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Abstract
Computational protein design has achieved several milestones, including the design of a
new protein fold, the design of enzymes for reactions that lack natural catalysts, and the
re-engineering of protein-protein and protein-DNA binding specificity. These achievements
have spurred demand to apply protein design methods to a wider array of research prob-
lems. However, the existing computational methods have largely relied on fixed-backbone
approaches that may limit the scope of problems that can be tackled. Here, we describe four
computational protocols - side chain grafting, flexible backbone remodeling, backbone graft-
ing, and de novo scaffold design - that expand the methodological protein design repertoire,
three of which incorporate backbone flexibility. Briefly, in the side chain grafting method,
side chains of a structural motif are transplanted to a protein with a similar backbone con-
formation; in flexible backbone remodeling, de novo segments of backbone are built and
designed; in backbone grafting, structural motifs are explicitly grafted onto other proteins;
and in de novo scaffolding, a protein is folded and designed around a structural motif.
We developed these new methods for the design of epitope-scaffold vaccines in which viral
neutralization epitopes of known three-dimensional structure were transplanted onto non-
viral scaffold proteins for conformational stabilization and immune presentation. Epitope-
scaffolds were designed using the different methods for three different epitopes from Human
Immunodeficiency Virus and Human Respiratory Syncytial Virus. In each case, the goal
was to design stable molecules with well-defined folding transitions and high affinities for a
virus-neutralizing monoclonal antibody. By experimentally testing our designed scaffolds,
we demonstrated that this goal was achieved by all four methods. Further, crystallographic
analysis of epitope-scaffolds designed by side-chain grafting and remodeling revealed excel-
lent agreement between design models and experimental structures. The epitope-scaffolds
designed here will serve as promising vaccine candidates. The computational design meth-
ods are generalizable and could be applied to other problems. Additionally they may be
valid alternatives to problems addressed in the past with more conservative strategies.
Suma´rio
Os me´todos computacionais existentes para o design de prote´ınas teˆm vindo a alcanc¸ar
objectivos nota´veis, tais como: o design de uma prote´ına com uma nova estrutura tridimen-
sional; o design de uma enzima com actividade catal´ıtica para a qual na˜o sa˜o conhecidos
outros catalisadores existentes na natureza e a manipulac¸a˜o das especificidades existentes
nas interacc¸o˜es prote´ına-prote´ına e prote´ına-DNA. O alcance das metas mencionadas po-
tenciou o interesse na aplicac¸a˜o de te´cnicas de design de prote´ınas em problemas bastante
diversificados. Ate´ enta˜o, a maioria dos me´todos computacionais utilizados na˜o permitiam
qualquer tipo de flexibilidade da cadeia principal. Esta restric¸a˜o na flexibilidade podera´
potencialmente representar uma limitac¸a˜o para os problemas que podem ser abordados
usando design computacional. Nesta tese esta˜o descritos quatro novos protocolos computa-
cionais: transplante de cadeias laterais, remodelac¸a˜o da cadeia principal, transplante de
motivos estruturais e o novo design de prote´ınas-suporte. Os quatro me´todos descritos di-
versificam o reporto´rio metodolo´gico existente relativamente ao design de prote´ınas; treˆs
deles incluem a utilizac¸a˜o de liberdade conformacional da cadeia polipept´ıdica. Resumida-
mente descrevem-se algumas caracter´ısticas que distinguem os diferentes me´todos: para o
transplante de cadeias laterais, estas sa˜o transplantadas para prote´ınas com conformac¸o˜es
da cadeia principal similares a`s conformac¸o˜es do motivo estrutural de interesse; na remod-
elac¸a˜o da cadeia principal, novos segmentos da mesma sa˜o constru´ıdos com sequeˆncias de
aminoa´cidos adequadas; no transplante de motivos estruturais, estes sa˜o transplantados
ignorando a conformac¸a˜o local das prote´ınas-suporte e e´ permitida flexibilidade na cadeia
principal adjacente para estabilizac¸a˜o do motivo transplantado; finalmente, no de novo de-
sign de prote´ınas-suporte, a maioria da cadeia polipept´ıdica tem liberdade conformacional,
suportando o motivo estrutural de interesse. Estas novas metodologias foram aplicadas na
gerac¸a˜o de prote´ınas para o suporte de ep´ıtopos; os ep´ıtopos, pertencentes a prote´ınas virais
com a estrutura tridimensional determinada, foram transplantados. A transplantac¸a˜o do
ep´ıtopo pretende assegurar a estabilizac¸a˜o estrutural, para que estes sejam apresentados
ao sistema imunolo´gico de forma eficiente. As prote´ınas-suporte foram criadas contendo
ep´ıtopos para os quais sa˜o conhecidos anticorpos neutralizantes pertencentes a dois v´ırus:
o Vı´rus de Imunodeficieˆncia Humana e o Vı´rus Sincicial Respirato´rio. Para ambos os v´ırus,
as prote´ınas criadas computacionalmente foram testadas experimentalmente demonstrando
ser termicamente esta´veis e possu´ırem elevadas afinidades de ligac¸a˜o com anticorpos neu-
tralizantes. As estruturas cristalinas das prote´ınas criadas computacionalmente esta˜o em
concordaˆncia com os modelos computacionais inicialmente gerados. A longo prazo estas
mole´culas podera˜o ser utilizadas para o desenvolvimento de vacinas. As metodologias com-
putacionais desenvolvidas sa˜o generaliza´veis e potencialmente u´teis para outras aplicac¸o˜es.
Os protocolos desenvolvidos constituem, tambe´m, alternativas via´veis para serem aplicados
em problemas de design computacional de prote´ınas que, anteriormente, foram abordados
com estrate´gias mais conservadoras.
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1Chapter 1
GENERAL INTRODUCTION
1.1 Protein Design - Historical Perspective
A long-standing goal of a wide scientific community is to be able to create tailored proteins
that efficiently perform desired biological functions. The three-dimensional structure of a
protein and its interaction partners is thought to determine the function of that protein,
and a major aim of structural biology is to dissect the relationship between structure and
function and to understand how different structural features govern different functions.
Though predicting the structure or function of a protein from its amino acid sequence
remains an unsolved problem, finding sequences compatible with a particular structure (and
function) may be more tractable, as first discussed by Drexler[1]. The process of selecting
sequences that will fold into a known structure was defined by Pabo[2] as the ”inverse
folding” problem and has been the strategy of choice to tackle most protein design problems
to date. One of the first attempts to employ a flavor of the inverse folding strategy was
reported by Gutte et al. in 1979[3] where a 34-residue polypeptide was designed, based on
rules extracted from the few known x-ray structures. A simple topology was idealized with
the purpose of binding to nucleic acids; with this back of the envelope topology they choose
an amino-acid sequence with a predicted secondary structure in agreement with the target
topology. After 30 years many of these principles are still employed. Remarkably, Gutte and
coworkers had the conceptual view of designing a structure to accomplish a defined function,
though as the field of protein design has progressed most studies have aimed lower, with
purely structural aims disregarding any functional purposes.
Structural biology has come a long way since the first attempts to rationally design
proteins, and the expanding Protein Data Bank[4] - currently holding approximately 70,000
protein structures - provides a wealth of structural information for the success of the inverse
folding strategy. Likewise, computational structural biology has flourished, based on massive
2amounts of experimental information available, active development of efficient algorithms
and vastly increased computational resources.
Ponder and Richards[5] elaborated on Drexlers suggestion and devised one of the first
computational methods to approach the inverse folding problem, by creating the concept of
”tertiary templates”. The tertiary templates consist on a set of sequences compatible with
a prototype crystal structure according to specified set of stereochemical rules. To sample
side chain degrees of freedom, Ponder and Richards used a ”rotamer” library approach while
keeping the protein backbone fixed. The computational algorithm favored combinations of
amino acids in the core free of steric clash but optimized the packing density.
Advances in protein computational design were also intimately related with advances in
molecular biology and DNA manipulation, which allowed for routine experimental charac-
terization of designed proteins. Hellinga and Richards, also pioneering protein designers,
described in 1991 the DEZYMER [6], a computer program able to search for constella-
tions of backbone positions in a protein to design ligand binding sites according to a pre-
defined geometry of interaction between ligand and protein. The design of a metal binding
site in thioredoxin was accomplished with DEZYMER, being one of the first successes of
computational-aided design[7].
1.2 Milestone Achievements in Computational Protein Design
1.2.1 Protein Stability Enhancement
After the first groundbreaking steps in computational protein design, many milestones en-
visioned by Drexler and Pabo have been achieved. One of the first applications of protein
computational design was the enhancement of protein stability, a central property for the
development of molecules with biological and therapeutic applications. In general, improve-
ments have been achieved by increasing the hydrophobic surface burial, in most of the cases
more hydrophobic residues in the redesigned core translate to improved protein stability[8].
It is worth mentioning that substitutions of polar amino acids by hydrophobic are not always
advantageous as showed in work from the Mayo laboratory[9, 10] , where by counting the
hydrogen bonds made by a particular residue, it was possible to identify which residues were
3important to keep intact. The same group demonstrated that other electrostatic principles
are also efficient approaches to improve protein stability, such as mutations that stabilize
the helix dipole and helix capping mutations[9, 10, 11].
1.2.2 Design of existing and novel protein folds
The complete re-design of existing folds or the design of a novel topology are strict tests
of the performance of energy functions and of our understanding of the physical chemistry
governing protein structure. The large number of sequences possible increases the demand
for energy functions able to discriminate which sequences are energetically more favorable
for a given fold. The test becomes even more stringent if we consider that computationally
designed proteins frequently have the correct secondary structure but often fail to attain
the desired tertiary structure, behaving as molten globules or partially unfolded protein
with tendency for aggregation. Dahiyat et al. described one of the first designs of a whole
protein structure in which the target topology was a 34 residue ββα zinc finger motif [12].
The algorithm relied on the dead-end elimination theorem for a rapid and efficient selection
of sequences and rotamers [13]. Different scoring functions were used for positions within
the protein core, surface, or a ”boundary” region between the core and surface. Core posi-
tions were designed allowing only hydrophobic amino acids, surface positions allowing only
hydrophilic, and boundary positions allowing both types of amino acids. The final designed
sequence had minimal sequence similarity to any zinc-finger sequence known by that time.
Interestingly, designed hydrophobic residues in the protein core replaced a native metal
binding site. The agreement between the computational model and determined solution
structure was 1.98 A˚ RMSD over the backbone, and similar core packing was observed in
both the model and solution structure.
The design of a new protein fold poses a more stringent test to the computational al-
gorithms because there is no pre-existing backbone template that may carry some bias to
native sequences [14, 15, 16, 17, 18]. Harbury et al. [19] designed a family of dimeric, trimeric
and tetrameric coiled-coils with pre-determined right-handed super-helical fold. This sem-
inal work explored structural diversity of the coiled-coils using algebraic parameterization,
4originally described by Francis Crick[20]. Right-handed coiled-coils were generated and de-
signed following an undecatad amino acid repeat in which 3 of the positions were restricted
to hydrophobic amino acids. A structure of a designed tetrameric coiled coil was solved
and showed a backbone RMSD of 0.2 A˚ compared to the computational model. Despite the
successful results, an obvious limitation is that this approach cannot be readily applied to
more complicated topologies that lack defined parametric descriptions. Kuhlman et al. de-
scribed the design of a novel protein fold (Top7)[21]. The authors devised a set of distance
constraints that defined a topology not yet observed in nature and employed Rosetta de
novo structure prediction[22] to generate the initial models for design (further described in
section 1.3). Through iterations between sequence design and structure optimization, low
energy sequence-structure pairs were found. Core positions were restricted to hydrophobic
amino acids while surface exposed were restricted to hydrophilic. The computational model
and the crystal structure of the design showed an RMSD of 1.2 A˚ and Top7 showed high
thermal stability. Top7 was unprecedented by showing that it is possible to sketch a protein
fold not observed in nature and design it to became a real protein. It was also unprecedented
in the use of backbone flexibility both to build initial design templates and to iteratively
search for low energy sequence-structure pairs (the use of flexibility will be further discuss
in section 1.4).
1.2.3 Interface Design
Beyond designing for structural recapitulation, the ultimate goal of protein engineers is to
be able to create functional molecules with biotechnological and therapeutic applications,
or research value where they can serve as probes to help the understanding of cellular
processes. Protein-protein interactions are central to many processes in cells, and the design
and manipulation of protein-protein interactions has been the subject and motivation for
many developments in protein computational design. As clearly stated by Karanicolas and
Kuhlman[23], interface design objectives typically fall into one of three categories: affinity
enhancement of naturally occurring interfaces, specificity switches in protein interactions,
and designing interactions from scratch which is yet to be attained.
5Tidor and co-workers reported a 140-fold improvement in affinity between an antibody-
antigen complex, achieved by searching for mutations with favorable electrostatic interac-
tions. Additionally, they showed better correlation in predicting affinity enhancing muta-
tions by only considering electrostatics interactions opposed to the interaction energy. From
a collection of other studies the decrease of the desolvation cost of the interface and the
increase of hydrophobic surface area buried in the interface seem like the most efficient way
to improve affinities between complexes[23].
Several successes have been reported in designing interface specificity. Multistate design
was one of the successful strategies, in which positive design favoring one ore more target
interactions and negative design disfavoring competing undesired interactions are carried
out simultaneously. Using such a strategy Havranek and Harbury reported the design
of selective coiled coil pairs [24]. More recently, Keating and co-workers designed specific
peptide partners for 19 of 20 human basic-region leucine zipper (bZIP) transcription factors.
The synthetic peptides were specific for the target family and not for the remaining 18
families. For fast computation of energies to the desired targets and competitor targets
it was used a cluster expansion method that allows for the conversion of structure-based
model into a sequence-base scoring function[25]. The cluster expansion method was trained
on a set of sequences that were modeled structurally. bZIP peptides are a fairly structurally
conserved family, so the question remains if such methods will be applicable to families
structurally more diverse[23].
According to the literature the use of multistate design seems to be required if the degree
of similarity of the competitors is high. Multistate design has also been used in a scheme
where the desired target is the interface to be designed and the negative target is the protein
in the absence of the binding partner. This scheme improves sequence recovery in interface
design (S. Fleishman personal communication) where the existence of a competing state
may compensate for inaccuracies in the energy function.
In the absence of appreciable similarity between competing states, strategies based in
positive design seem to be efficient and have been employed to modulate calmodulin binding
specificity. Shifman and Mayo were able to maintain the affinity for the target interaction
(calmodulin - smMLCK) while reducing the affinity for other 6 known interacting peptides
6by 1.5 to 86 fold[26]. Soon after, Reina et al. reported the engineering of PDZ domains to
recognize new targets using a conceptually similar strategy[27].
Another important achievement in the design of interfaces of macromolecules was the
rational redesign of protein-DNA interactions to modulate binding and cleavage specificity
of a homo-endonuclease (Mso). Base-pair substitutions were performed and clusters of
residues responsible by accommodating the newly introduced base pair were redesigned.
The specificity switch achieved for the new DNA sequence relative to the wild type was
10000 fold, and the computational design showed good agreement with determined crystal
structure [28].
1.2.4 De novo Enzyme Design
De novo design of catalytic activities not observed in natural enzymes has been another
major goal of protein design since the early days when Drexler mentioned the possibility
of designing molecular machines[1]. Hellinga and Richards contributed critically with the
idea of searching constellations of amino acids in which functional groups could be placed
in a pre-defined geometry[7]. Later on, matching algorithms using geometrical hashing
were developed by multiple groups to identify structurally suitable scaffold proteins for
enzymatic sites[29]. Baker and co-workers reported the first enzymes that catalyze reactions
not observed in nature by employing a hashing algorithm to find positions to host catalytic
motifs that had been optimized by quantum mechanical calculations[30, 31, 32]. In both
cases the catalytic activity of the computational designs was far less than the activities
observed in natural enzymes, nevertheless these designs served has a proof of principle,
posed stringent tests to the understanding of enzyme catalysis, and also provided valuable
starting points for directed evolution.
1.2.5 Scaffolding with Rational Approaches
The transplantation of side chains, structural motifs, binding sites or active sites from
native proteins to other non-related proteins can be generally categorized as scaffolding.
Typically for these design problems there is a first stage to select host proteins (scaffolds), a
7second stage of transplantation of the motif of interest, and a third stage to design first and
second shell residues in order to find energetically favorable sequences of amino acids. In
addition to DEZYMER, several other computational algorithms have been reported, that
find appropriate geometries to graft side chains of linear or non linear sequences[33, 34, 35].
At least two reports have described side chain grafting of helical motifs to the transcription
factor GCN4 Serrano and colleagues transplanted part of an interleukin-4 binding site[36]
and Kim and colleagues grafted a region of HIV gp41[37]. Both of these grafting exercises
were successful, in the sense that several designed molecules showed high affinities to the
intended targets, nevertheless both skipped a systematic search for accepting scaffolds basing
the scaffold selection in secondary structure similarity and both relied on the alpha-helical
geometry. A more systematic approach for scaffolding was taken in Liu et al.[35] in which a
protein-protein interaction was created by grafting the key residues of one of the wild type
proteins onto a non-related protein. In this study, three residues were grafted onto a scaffold
identified by a geometrical hashing search of the PDB; the KDs to the target binding site
were 100 fold higher in comparison to the wild type protein. The computational design was
not confirmed by experimental structural characterization, nevertheless functional studies
in vivo showed the expected activity.
1.3 Rosetta - The Tool
The Rosetta software package was initially created to perform ab initio protein prediction
[22]. Since then, Rosetta has been a fast-developing platform with a myriad of applica-
tions regarding to macromolecular modeling and design. Besides protein structure predic-
tion, Rosetta has acquired many other functionalities such as loop modeling[38], protein
docking[39] and small molecule docking[40], protein design, phasing diffraction data with
de novo models[38], usage of NMR[41] and cryoelectron microscopy[42] data for structure
refinement, DNA-protein interface design[28, 43] and RNA folding[44], among others.
The core features of Rosetta that enable this variety of modeling applications are low
and high-resolution energy functions, a variety of conformational sampling methods, and
use of both Metropolis Monte Carlo criteria and minimization algorithms to reach energy
minima.
8In stages where a large conformational space is sampled, a coarse-grained low resolu-
tion potential is often used first, together with a reduced description of the protein struc-
ture where side chains are represented as centroids. The low resolution energy function
is dominated by several statistical potentials such as solvation and electrostatics derived
from observed residue distributions on protein structures. Explicit hydrogen bonds are not
considered but probabilistic terms to evaluate secondary structure motifs are taken into ac-
count. Steric overlaps between the side chain centroids and backbone atoms are penalized
but overall compact structures are favored by computing van der Waals interactions and
gyration radius of the protein. After a first coarse-grain exploration of the energetic land-
scape, typically several local minima are found; to search for the lowest energy minimum all
the atomic detail is added to the protein structures, allowing a more accurate calculation
of the energetic contributions. The full-atom energy function computes the interactions
between buried atoms in an attempt to capture the high energetic cost of void volumes in
the protein core, van der Waals interactions are modeled with a Lennard-Jones potential.
The solvation is included using the implicit solvation model of Lazaridis and Karplus [45]
and the energy for explicit hydrogen bonds is computed using a secondary structure and
orientation dependent potential[46]. In terms of conformational sampling strategies there
is a wide variety of moves that can be applied to the polypeptide chain depending on the
atomic detail of the sampling stage and also of the degree of conformational diversity de-
sired. Generally, at a low resolution stages of sampling, moves that yield large structural
changes are needed, fragment insertion is typically the first stage of conformational sam-
pling for standard protocols as de novo structure prediction and loop prediction. Fragment
libraries are constructed from short fragments of known protein structures, with a residue
window of length 3 and 9, and are selected according sequence identity, secondary structure
or a mixture of both. A fragment insertion replaces the torsion angles of the polypeptide
chain with the torsion angles of the fragment. After the fragment insertion stage several
types of moves are employed with a finer sampling scope: random torsion angle pertur-
bation, selection of globally non-perturbing fragments and torsion angle variation to offset
global perturbations of the structure. At high resolution, to further sample the local con-
formational landscape the geometries are optimized by multiple torsion angle perturbations
9followed by rotamer optimization and continuous gradient based minimization of side chain
and backbone torsion angles. The main focus of the work presented here is protein design,
it is worth mention that RosettaDesign[15] shares the same principles described for the high
resolution energy function. Different amino acids are considered in each sequence position
and side-chain conformation included in a rotamer library are sampled[47]. A Metropolis
Monte Carlo procedure is used to accept or reject the move that consists in exchanging one
rotamer for another at a randomly chosen position.
Currently, Rosetta is a flexible platform for molecular modeling providing scoring func-
tions and conformational sampling moves suited for a wide range of resolutions. Due to its
modular architecture, data derived from a variety of experimental techniques can be easily
used to guide and validate computational calculations.
1.4 Fixed versus Flexible Backbone Design
As briefly reviewed here, many successes using computational protein design have been
reported, however only a few notable exceptions allowed backbone flexibility in conjunction
with design calculations. The prospect for generalized use of flexibility in computational
protein design holds the promise of meeting the challenges for the next generation of protein
engineering. It is reasonable to expect that flexible backbone modeling will open new
perspectives: allow the design of more efficient enzymes by trying to model more precise
geometries for catalytic machineries; design of conformational and specificity switches; and
fundamental understanding of the relationship between function and dynamics in proteins.
Utilizing an existing structure to be designed with a fixed backbone approach guarantees
that such conformation is possible and the design problem is reduced to find the combination
of amino acids that best fit the target conformation. On the other hand, if the design
template has never been observed the problem becomes more complex because there are no
guarantees that the template conformation is realistic.
Besides the milestone designs by Harbury et al. and Kuhlman et al., mentioned above,
backbone flexibility has been used to design a loop with sub-angstrom accuracy[48] and to
switch the substrate specificity of an enzyme[49]. Backbone flexibility in the first report was
achieved by small perturbations of the backbone and in the second by a fragment insertion
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strategy.
Given the promise and current limitations of flexible backbone protein design, it is im-
portant to pursue new methods and extensions of the existing methods . Several important
questions on flexible backbone design will be addressed in this thesis: i) How realistic is the
backbone conformational space sampled?; ii) Can we productively bias the conformational
sampling by adding functional and structural constraints? ; iii) How to discriminate good
from bad designs?; iv) Can we inform high-throughput selection techniques using compu-
tational design ? By providing some solutions to these problems, it is hoped that we have
advanced the field of protein design and that others will build on the work presented here.
1.5 Biological Relevance and Thesis Overview
1.5.1 Biological Relevance
The current structural knowledge regarding pathogens and other disease-related targets
provides many opportunities to devise structure-based strategies with potential therapeutic
applications. The transplantation of broadly neutralizing epitopes sets itself as a tempting
strategy to design immunogens to re-elicit neutralizing antibodies, and consequently being
useful as vaccine candidates, so called retrovaccinology approach[50]. Current successful
vaccines contain either the entire inactivated pathogen or isolated molecules known to gen-
erate protective immunity. Despite the considerable success of traditional empirical vaccine
design approaches, many pathogens have eluded vaccine design with these approaches. Two
such viruses are used as case studies in this work - HIV (Human Immunodeficiency Virus)
and RSV (Respiratory Syncytial Virus). Native antigen molecules are adapted to escape
rather than induce immunity, and undesired properties for efficient induction of neutralizing
responses are observed in the native antigens. In principle these undesired properties can
be optimized by rational methodologies if structural knowledge is available. Examples of
such optimization include: trimming variable regions, reducing multi-domain proteins to
minimal domains that contain the neutralizing epitopes, and stabilizing the conformation
of neutralizing epitopes. Many of these potential improvements are directly related to an
important challenge for immunogen design and fundamental immunology, that is to under-
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stand and engineer immunogenicity and learn how to make an epitope more ”obvious” to
the immune system. Rational approaches can be devised and tested to overcome the lack of
knowledge about the principles that govern immunogenicity, in an attempt to conceptualize
a set of practical strategies that will allow to improve immunogenic properties.
Considering all the hurdles with traditional approaches to generate useful immunogens
for pathogens that still lack vaccine candidates, we sought to use rational methodologies
to transplant broadly neutralizing epitopes to non-related protein scaffolds. A successful
transplantation could overcome several of the culprits identified on native molecules - for
example this strategy will allow the presentation of epitopes that are only transiently ex-
posed on the pathogen, for example it is thought that the 4E10 epitope on HIV gp41 is only
available on the virus-cell fusion stage[51]. Additionally, a successful transplantation would
also allow for precise stabilization of the epitope conformation recognized by the broadly
neutralizing antibodies - hence scaffolding is a promising rational strategy to try to re-elicit
broadly neutralizing antibodies.
At the beginning of my project the state of art of both immunogen and computational
design was rather different. Reports of rational and structure-based approaches applied to
immunogen design were sparse; the aims set for my PhD were to develop methods that would
allow dealing with a variety of design challenges. In the process of developing the design
methodologies we aimed to generate useful reagents for the vaccine research community.
Methodologically, approaches using flexible backbone design had only been described in few
reports [19, 15]. Due to the nature of the design problems we were facing, we aimed to
develop methodologies to routinely incorporate flexible backbone in computational design
calculations.
1.5.2 Thesis Overview
In my project I developed and applied computational techniques to transplant broadly neu-
tralizing epitopes from HIV and RSV to carrier proteins, the epitope-scaffolds. Due to the
structural diversity and complexity of different epitopes, several computational methods had
to be developed to successfully design epitope-scaffolds.Chapter 2 describes a fixed backbone
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design method, side chain grafting, that was developed to transplant linear epitopes. The
matching stage for selection of acceptor protein scaffolds relied mostly in two criteria: back-
bone similarity between the acceptor scaffold and the epitope of interest; and structural
compatibility between the acceptor scaffold and the antibody binding orientation. Com-
putational designs were structurally and biochemically characterized, and immunogenicity
studies were performed.
A natural continuation ion to the design of the first generation epitope-scaffolds and
also following-up the results from immunogenicity studies from the previous chapter, in
Chapter 3 describes two strategies to improve the immunogenic properties of the epitope-
scaffolds. Two strategies were attempted to improve the immunogenic response to the
epitope of interest: domain trimming and resurfacing. For the domain trimming, I devised
a flexible backbone design protocol to rebuilt and design de novo segments with pre-defined
secondary structure. Another rational approach described is resurfacing that uses fixed
backbone design to change the majority of the epitope-scaffold surface residues creating
panels of molecules where the common trait is the epitope. Experimental results validate
the novel flexible backbone design and also show desirable biophysical properties of the
resurfaced designs.
Most of the neutralizing epitopes are not contiguous, instead they are defined by several
discontinuous segments of the protein that interacts with the antibody. As consequence, the
method presented in Chapter 2 was inappropriate to deal with complex structural motifs.
Chapter 4 describes the development of a new method to transplant complex epitopes. The
flexible backbone philosophy described in Chapter 3 was extended to the modeling of several
segments in a protein such that the complex epitope graft would be structurally supported.
Due to the complexity of the design problem, computationally based directed libraries were
designed and in vitro evolution was leveraged by the computational protocol, providing a
fast and efficient protocol for screening and selection of sequences with improved binding
affinity to the target antibody.
Most scaffolding strategies are inherently limited to the existence of scaffolds compatible
with the epitope of interest. To further expand the modeling strategies available for epitope
transplantation, in Chapter 5 I developed a computational method for ”de novo” design of
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epitope-scaffolds. This method only requires a target topology compatible with the desired
epitope, dismissing the atomic detail considered by the matching algorithms described in
the previous chapters. In principle, it is not required that the target topology has been
previously observed in nature, any ”back-of-the-envelop” topology should be sufficient to
serve as input for the protocol. The computational methodology is conceptually different
from the previous protocol in which a structural motif is forced in a mostly rigid scaffold. In
contrast, in the new ”de novo” approach, only the epitope is rigid and the rest of the scaffold
is moveable in order to achieve the maximal support for the rigid segment. To evaluate the
performance of the method computational designs were experimentally characterized. It
is important to reinforce that the methods developed throughout my PhD project were
applied to epitope scaffolding and immunogen design, nevertheless they are generalizable
and readily applicable to other biological problems such as the design of protein inhibitors
and enzymes.
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Chapter 2
COMPUTATIONAL DESIGN OF EPITOPE-SCAFFOLDS ALLOWS
INDUCTION OF ANTIBODIES SPECIFIC FOR A POORLY
IMMUNOGENIC HIV VACCINE EPITOPE
2.1 Abstract
Broadly cross-reactive monoclonal antibodies define epitopes for vaccine development against
HIV and other highly mutable viruses. Crystal structures are available for several such
antibody-epitope complexes, but methods are needed to translate that structural informa-
tion into immunogens that re-elicit similar antibodies. We describe a general computational
method to design epitope-scaffolds in which contiguous structural epitopes are transplanted
to scaffold proteins for conformational stabilization and immune presentation. Epitope-
scaffolds designed for the poorly immunogenic but conserved HIV epitope 4E10 exhib-
ited high epitope structural mimicry, bound with higher affinities to monoclonal antibody
(MAb) 4E10 than the cognate peptide, and inhibited HIV-neutralization by HIV+ sera.
Rabbit immunization with an epitope-scaffold induced antibodies with structural speci-
ficity highly similar to MAb 4E10, an important advance toward elicitation of neutralizing
activity. The results demonstrate that computationally designed epitope-scaffolds are valu-
able as structure-specific serological reagents and as immunogens to elicit antibodies with
pre-determined structural specificity.
2.2 Introduction
A protective HIV vaccine, or a universal flu vaccine, likely will elicit antibodies that block
infection of diverse circulating strains of HIV or Influenza. Several anti-HIV antibodies with
broad neutralizing reactivities have been isolated from natural infection, and approximately
25% of HIV-1-infected individuals produce broadly-neutralizing sera [52], but efforts to elicit
such responses by vaccination have failed. Anti-influenza broadly neutralizing antibodies
(bNAbs) also have been characterized [53, 54, 55, 56], but the annual influenza vaccine elicits
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potent neutralizing antibodies only against the vaccine strains and closely-related isolates.
The anti-HIV MAb 4E10 neutralizes 98% of HIV strains [57] hence elicitation of 4E10-
like antibodies is a major goal for HIV vaccine design. 4E10 binds a contiguous epitope in
the Membrane Proximal External Region (MPER) of gp41 just N-terminal to the transmem-
brane domain[58, 59], an epitope that is likely only transiently exposed during viral fusion
with the target cell [51]. Nuclear magnetic resonance structural analysis of MPER peptides
in lipid micelles found a kinked helix partially embedded in lipid [60]. Crystal structures of
MAb 4E10 in complex with gp41 peptides revealed that 4E10 binds to a helical epitope in
an end-on manner with the N-terminus and one face of the helix docked into a hydrophobic
cavity on the antibody; the bound epitope adopts a short 3/10 helix followed by an alpha
helix, and conserved HIV side chains from both regions make significant antibody contacts
[61, 62, 63, 64]. The antibody also has a long, hydrophobic complementarity-determining
region H3 (CDRH3) loop, which does not bind directly to the helical epitope but which may
provide contacts to the viral lipid membrane and contribute to neutralization [61, 62, 63, 64].
Here, as a first step to elicit antibodies with the binding and neutralizing properties of MAb
4E10, we aimed to develop immunogens that would elicit antibodies with the exact binding
specificity of MAb 4E10 for its core peptide epitope.
A major hurdle confronting 4E10-vaccine design is that the epitope is naturally poorly
immunogenic. While 4E10-like activity has been detected in HIV+ patients with broadly-
neutralizing activity, the frequency is low (∼ 5%)[57, 65, 66]. Furthermore, previous at-
tempts to elicit 4E10-like antibodies by vaccination using soluble trimeric gp140[67], VLP-
membrane-anchored gp41 variants[68], or a gp120 construct with the 4E10 epitope embed-
ded in the highly immunogenic V2 loop [69], failed to elicit reactivity against the epitope
primary sequence. MPER peptides anchored to liposomes or hepatitis B surface antigen
particles have elicited modest responses against 4E10 peptides [70, 71], but whether these
responses were directed to the 4E10 epitope or other epitopes was not determined. In none
of these cases was the helical epitope conformation necessarily stabilized, though in all cases
the antigens did bind to MAb 4E10.
Crystallographic analysis of several anti-HIV [72, 62, 73, 74] and anti-Influenza[75, 55]
bNAb/epitope complexes, combined with advances in computational protein design [21],
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provide new opportunities for structure-based vaccine design [76]. Here we pursued a strat-
egy of stabilizing an epitope in its antibody-bound conformation, and presenting that stabi-
lized epitope in an immunogenic format, in order to elicit antibodies with structural speci-
ficity similar to the target antibody. Specifically, we engineered epitope-scaffold immunogens
in which the HIV 4E10 epitope was transplanted by computational design to small, non-viral
scaffold proteins for conformational stabilization and presentation to the immune system
without the immunodominant variable regions typical of persistent pathogens. The compu-
tational design methods are general and should be applicable for structural stabilization of
a variety of contiguous epitopes of different conformations from HIV, Influenza and other
viruses
2.3 Materials and Methods
2.3.1 Computational design of epitope-scaffolds
The automated matching and design stages of the side-chain grafting protocol were imple-
mented in the Rosetta [77] modeling platform. The matching stage exhaustively searched
13337 single chains from the PDB [4] for backbone similarity with the 4E10 epitope by
computing RMSD (Root Mean Square Deviation) between residues 671-680 or 672-680 in
PDB ID:2FX7 [61] and all possible protein segments using matched-width sliding windows
in the query scaffolds. All hits with RMSD < 1 A˚ (or RMSD/length < 0.1) were retained
if backbone clash with antibody was less than 100 energy units. Epitope side-chains were
transferred to all-glycine versions of the remaining hits, and then interfacial side-chain tor-
sions and the rigid-body orientation of antibody and epitope-scaffold were optimized by
minimization [78]. Highly conserved epitope side-chains W672, F673, I675, L679 and W680
were transplanted to all scaffolds. At moderately variable epitope positions (671, 674, 676),
the most energetically favorable of the common HIV side-chains was generally transplanted
(N, S, or G at 671; D, S, or N at 674; S or T at 676). Native scaffold side-chain rotamers
outside the epitope were recovered, and residues near (heavy atom distance < 4 A˚) the
epitope or the antibody were designed, categorized as ’intra’ and ’inter’ positions respec-
tively. Inter residues were allowed to be ALA, GLY, SER, THR and intra positions were
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allowed to be all amino acids except CYS. Epitope-scaffolds were ranked by antibody bind-
ing energy and human-guided design was performed on the best to: (a) revert unnecessary
or potentially destabilizing mutations; (b) eliminate unpaired cysteines and undesired func-
tional sites; (c) trim extraneous domains; (d) optimize solubility. In two cases (T93 and
T278) more advanced flexible backbone design was performed for domain trimming (T93)
or fusion to Maltose Binding Protein (MBP) for stabilization (T278); discussion of these
methods is beyond the scope of this manuscript and will be reported elsewhere (Correia et
al., submitted JMB).
2.3.2 Protein expression, purification and characterization
DNA segments encoding epitope-scaffold constructs were synthesized with optimized codon
usage and RNA structure (Codon Devices, Genscript Corp.), subcloned into pET29 (EMD
Biosciences) and transformed into BL-21 Star E. coli (Invitrogen). Single colonies were ex-
panded from starter cultures in Luria Broth into ZYP-5052 auto-induction media [79] plus
Kanamycin (100 mg/mL), incubated for four hours at 37◦C and then overnight at 18◦C.
Cultures were then pelleted and stored at -20◦C. Pellets were resuspended in standard
buffer (50 mM Tris, 500 mM NaCl, 10 mM Imidazole, 0.5 mg/mL lysozyme), sonicated on
ice and clarified by centrifugation. Supernatants were tumbled with 10 mL of nickel-NTA
resin (Superflow NTA, Qiagen) for 30 min at 4◦C. The resin was then rinsed twice with
10 mM imidazole, once with standard buffer plus 20 mM imidazole and eluted with stan-
dard buffer plus 250 mM imidazole. Eluates were concentrated by ultrafiltration (Amicon
Ultra, Millipore) and filtered through 0.22 micron Ultrafree-MC spin columns (Millipore).
Epitope-scaffolds were then purified by preparative size exclusion chromatography (SEC) on
Superdex 75 16/60 columns (GE Healthcare) at room temperature in 25 mM PIPES (pH =
7.0), 150 mM NaCl, 1 mM EDTA and 0.02% w/w sodium azide (PNEA). Epitope-scaffold
purity was confirmed by SDS-PAGE and analytical SEC; analytical SEC ± target NAb (Su-
perdex 75 or 200 10/30 columns, GE Healthcare) in PNEA was used to assay qualitative
binding, multimer state, monodispersivity and complex stoichiometries. Protein concentra-
tions were determined with the BCA protein assay (Pierce); solution thermostabilities (Tm)
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were determined by circular dichroism (CD) spectroscopy with Jasco J-815 instrumentation
as previously described [64].
In order to prepare endotoxin-free protein for immunization studies, bacterial pellets
were alternately resuspended in detergent buffer (50mM NaH2PO4, 500mM NaCl, 10mM
imidazole, 0.5mg/mL lysozyme, 0.01mg/mL DNAse, 0.1% Triton X114) and loaded IMAC
resin was alternately initially washed in 10 mM imidazole, 50mM NaH2PO4, 500mM NaCl,
0.1% Triton X114. Preparative SEC purification was carried out in sterile PBS on columns
just previously cleaned with a bolus of 1M NaOH. Endotoxin levels were assayed with the
PyroGene Recombinant Factor C Endotoxin Detection System (Lonza). Protein prepara-
tions were further purified using the ProteoSpin Endotoxin Removal Maxi Kit (Norgen) if
endotoxin levels exceeded 2EU/50 µg at a [protein] of 1 mg/ml, the maximum level accepted
for immunization.
2.3.3 Crystallization and crystallography
Crystals of epitope-scaffolds and epitope-scaffold-Fv complexes were grown by vapor diffu-
sion, under the conditions shown in Table 2.1. The complexes were purified as such by SEC
prior to crystallization. Diffraction data were collected at -170 ◦C on cryopreserved crystals,
as detailed in Table 2.2, and processed with d*TREK (Pflugrath, 1999). Initial structure
factor phases were determined by molecular replacement (search models in Table S3), using
the program Phaser [80] or MolRep [81], as implemented under CCP4i [82]. Successive
rounds of modeling and positional and individual B factor refinement were carried out with
Coot [83] and Refmac5 [84]. Five of the six structures were submitted to the TLSMD server
[85, 86] where TLS groups were defined. Structure validation was carried out with Procheck
[87], the MolProbity server [88] and the RCSB ADIT validation server. The structures were
deposited in the PDB [4] with accession codes in Table 2.1. Data collection and structure
refinement statistics are in Table 2.2.
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Table 2.1: Crystallization conditions and structure determination.
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Table 2.2: X-ray diffraction data and refinement statistics for the epitope-scaffold structures.
T18 T88-Fv T93-Fv T117 Tl61 T246 
D ata Collection 
Space group P6522 P2 1 P212,2, P2,2,21 C222, P2,2,2, 
Cell dimensions 56.4, 56 .4, 324.1 A 75.9 , 145.9, 78.6 A; 92.5 ° 53.0, 88.6, 150.0 A 49.2, 82.0, 94.2 A 40.7, 75.4, 79 .6 A 91.6, 94.9, 108.4 A 
Resolution (A) ' 48.30-2.30 (2.38-2.30) 28.01-2.65 (2 .74-2.65) 29 .54-2.70 (2.80-2.70) 49 .21-1. 90 (1. 97-1. 90) 32.64-2.00 (2.07-2.00) 28.82-2.50 (2.59-2.50) 
Number observed reflections' 115 ,705 (8910) 190,285 (17,961) 66 ,868 (4874) 133,236 (12 ,691) 38,309 (2008) 150,445 (12,033) 
Number unique reflections' 13,770 (1304) 49 ,017 (4883) 19,356 (1705) 30,053 (2886) 8462 (755) 33,220 (3180) 
Redundancy' 8.40 (6.83) 3.88 (3.68) 3.45 (2.86) 4.43 (4.40) 4.53 (2.66) 4.53 (3.78) 
Completeness (%)' 93.7(91.5) 98.9 (98.6) 96.2 (85.5) 97.5 (95.2) 98.3 (89.9) 99.5 (96.8) 
Rmerge' 0.086 (0.373) 0.095 (0.376) 0.102 (0.405) 0.057 (0.341) 0.052 (0.185) 0.107 (0.429) 
Average I/ o (I)' 9.0 (3.9) 9.4 (2.7) 7.1 (2.2) 17.2 (2.6) 18.6 (4.0) 6.6 (2.0) 
Structure R efinement 
Resolution (A) 46.78-2.30 26.70-2.65 28.99-2.70 31.50-1.90 27.37-2.00 28.82-2.50 
R work/ R free 0.258/ 0.290 0.222/ 0.270 0.243/ 0.335 0.223/ 0.279 0.204/ 0.260 0.257/ 0.301 
Numb er of atoms: 
Protein 1275 9019 5112 2494 925 3155 
Water 55 132 82 262 127 94 
Other 4 (1 ethylene glycol) 4 (1 ethylene glycol) 15 (3 phosphates) 55 (11 sulfates) 
r.m.s. deviations from ideal 
values: 
bond lengths (A) 0.009 0.006 0.009 0.009 0.011 0.014 
bond angles (0) 1.146 0.927 1.132 1.056 1.004 1.189 
chiral volume (A3) 0.070 0.054 0.051 0.061 0.057 0.062 
Ramachandran plot statistics: 
most favored regions (%) 95.8 90.4 90.0 94.1 100.0 99.4 
additional allowed regions (%) 3.5 9.2 9.6 5.9 0.0 0.6 
generously allowed regions (%) 0.0 0.0 0.0 0.0 0.0 0.0 
disallowed regions (%) 0.7 (1 res. 2) 0.4 (4 res .3) 0.3 (2 res .3) 0.0 0.0 0.0 
Estimated coordinate error 
(maximum likelihood e.s.u.) (A) 0.19 0.240 0.17 0.137 0.208 
Average B factor: 
Protein 66.4 57.2 68.1 43.6 45.1 76.6 
Water 58.6 49.7 49.6 49.7 50.9 73.7 
Other 85.3 53.2 82.4 96.3 
, Values in parentheses correspond to the highest resolution shell. 
2 Residue 129, which is in a y turn conformation, as is the 1.5 A resolution parent structure lZ6N. 
3 Fv light chain residue 52 (51 by Kabat numbering) of all four chains, which is in a highly conserved y-turn conformation. 
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2.3.4 Sera Analysis and Imunizations
Luminex Multiplex Assay
4E10 peptides with three lysines added to their C-termini were amine-coupled to Bio-plex
beads (Biorad, CA) (12µg peptide/100µl beads) as described by the manufacturers protocol.
Serially diluted sera (pre- and post-immunization) or MAb 4E10 were incubated with the
bead cocktail for 1hr at RT. After four washes, beads were incubated with anti-rabbit or
human PE-conjugated secondary Ab for 1 hr at RT. A final wash step was performed prior
to analysis on a Luminex 200 System (Invitrogen, CA). Relative avidity was computed by
subtracting peptide-matched, pre-bleed mean fluorescent intensity (MFI) from each sample
and then normalizing to the experiment-matched MFI for bNAb 4E10 binding to wild-type
4E10 peptide.
Peptide ELISA
Binding of rabbit sera or bNAb 4E10 to 4E10 peptide (NWFDITNWLWYIRKKK [67] ),
alanine-mutant 4E10 peptides, and epitope-scaffolds was assessed by ELISA as previously
described [67].
Epitope scaffold competitive ELISA
Rabbit sera (1:25) were incubated with epitope-scaffolds (100 µg/mL) for 1 hr, and then
the mixture was added to ELISA plates coated with recombinant gp41 (HxB2) (0.5 µg/mL)
(Meridian Life Science) for 90 min at 37 oC. The binding of antibodies to gp41 was detected
as above for the peptide ELISA.
Competing the neutralizing activity of HIV-1+ sera by epitope-scaffolds
Epitope-scaffolds were tested for their ability to inhibit the neutralizing activity of plasma
VC10028 as previously described for peptide inhibition [66].
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Immunizations
Rabbits were immunized monthly at the Pocono Rabbit Farm and Laboratory Inc (Canaden-
sis, PA) with epitope-scaffolds mixed in PEI (Polysciences, Inc) or QS21 (Antigenics, Inc);
0.2 mg protein in 0.2 mL of PBS was administered into the two hind legs (0.2 mL per in-
jection site). KLH-peptide immunizations were performed by GenScript Corp (Piscataway,
NJ); rabbits were immunized with 0.5mg KLH-peptide and Complete Freunds Adjuvant,
and boosted at weeks 2, 5 and 8 with 0.5mg KLH-peptide and Incomplete Freunds Adjuvant.
KLH-peptide sera was tested from day 0 and week 10.
Statistical analyses
We performed statistical analyses using a one-tailed Students t-test to obtain p-values on
the significance of relative avidity levels below specified thresholds.
2.4 Results
2.4.1 Computational design of epitope-scaffolds
We designed a total of 103 4E10 epitope-scaffolds by the side-chain grafting method (models
representative of the variety of scaffold topologies are shown in Fig 2.1).
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Figure 2.1: Models of 4E10 Fv/epitope-scaffold complexes. The helical 4E10 epitope (yel-
low) was transplanted from the 4E10 Fab/gp41 peptide complex (boxed at top left) onto
different scaffold proteins (red).
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This method entailed ’matching’ and ’design’ stages. In the automated ’matching’
stage, a subset of the Protein Data Bank [4] was exhaustively searched for scaffold pro-
teins with a surface-exposed backbone segment similar in conformation to the 4E10 epitope
(NWFDITxxLW in PDB ID: 2FX7[61]). The resulting ’hits’ were filtered first by backbone
clash with the antibody and second by antibody-epitope binding energy (epitope side-chains
were transferred to the scaffold and energy minimization [78] was used to optimize antibody
and epitope side-chain conformations as well as the antibody-scaffold rigid-body orienta-
tion). Scaffolds selected in the ’matching’ stage were taken to the semi-automated ’design’
stage in which amino acids were designed for scaffold positions outside the epitope. The
’design’ stage aimed to ensure scaffold stability and solubility, avoid additional interactions
between scaffold and antibody, support the optimized epitope side-chain conformations,
eliminate undesired functional sites, and trim extraneous domains.
2.4.2 ’Validated’ epitope-scaffolds are stable and bind MAb 4E10 with high affinity
Epitope-scaffolds were expressed in E. coli, purified by immobilized metal affinity chro-
matography and SEC, and screened for antibody binding in qualitative SEC assays. Con-
structs were validated if they expressed as soluble protein (not within inclusion bodies) and
were purifiable to stable, soluble species that bound antibody by SEC; non-validated con-
structs were eliminated from further consideration. A total of 135 constructs were tested for
expression (103 designs plus 32 purification tag variants), and of those, 24 different designs
(23% of 103 designs) were carried forward for quantitative analysis of bNAb-binding by
SPR. Biophysical data are collected in Table 2.3 for the representative set of 10 validated
4E10 epitope-scaffolds depicted in Figure 2.1, and background information on each scaffold
is provided in Table 2.4.
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Table 2.3: Solution properties of 4E10 epitope-scaffolds.
1: Epitope-scaffold was immobilized by direct amine-coupling on CM5 chip or by biotinylation and capture on SA chip.
2: 4E10 IgG was captured by amine-coupled anti-human IgG.
3: Coupling epitope-scaffold to chip results in an inactive surface, likely due to lysine residues neighboring the epitope.
4: Stated value is an upper limit on the KD ; off-rate was too slow to fit kinetics.
Italicized values: SPR data were fit using a 2-state interaction model; the second on-rate has units of sec−1.
ND: experiment not performed
For all reported values, standard error is ≤±3 of the last significant figure.
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Table 2.4: Design information on the 4e10 epitope-scaffolds. N Residues reports the size
of the parent scaffold protein. N Residues Deleted tells the number of residues deleted
from the parent. N mutations counts the mutations to accommodate the 4e10 binding site,
remove extra contacts with the 4E10 antibody and enhance protein solubility. Epitope
Transplanted reports HIV sidechains on the epitope-scaffold, the dotted positions represent
scaffold positions at which HIV sidechains were not transplanted. Epitope RMSD Model
reports the root mean square deviation between the backbone of the 4E10 gp41 peptide
(PDB ID: 2FX7 [61]) and the parent scaffold. Expected Multimer State reports the expec-
tations based on our analysis of multimer state in the parent scaffold crystal packing, our
analysis of the literature regarding the parent scaffold, and on predicted effects on multi-
merization due to epitope transplantation (e.g. T117 parent was a dimer but we introduced
the epitope at the dimer interface so a monomer was expected in the epitope-scaffold). Ex-
pected Fv-Binding Stoichiometry reports our expectations based on the number of epitopes
transplanted to each monomer (e. g. we transplanted 2 epitopes onto T176) and on the
exposure of epitopes on any expected multimers (e. g. T18 is a dimer with both epitopes
exposed).
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To facilitate interpretation of bNAb-binding experiments, the epitope-scaffold solution
multimer state and stoichiometry of Fv-binding were assessed by static light scattering
(SLS) and SEC. Examples of SEC data are given in Figure 2.2. Solution multimer state
and Fv-binding stoichiometry accorded with expectation (monomer and 1:1, or dimer and
2:2 for T18) for 5 of 12 epitope-scaffolds (T18, T36, T93, T161, T278). The other epitope-
scaffolds formed unexpected multimers that dissociated in the presence of Fv, suggesting
that multimers self-associating through the hydrophobic 4E10 epitope were in equilibrium
with rare monomers. Aggregation was noted previously for gp120 with engrafted MPER
sequences [89]. Multimerization of some 4E10 epitope-scaffolds will be addressed in detail
in a separate manuscript (Xu et al., in preparation).
Figure 2.2: Size exclusion chromatography analysis of epitope-scaffolds in complex with
4E10. Epitopes-scaffolds (blue), 4E10 Fv (red) and complexes (purple) are shown for T88
(left) and T117 (right). Molecular weights (Mr) for the species at absorption peaks (arrows)
are T88: ∼40kD (SEC) or 32.2kD (SLS); T88/Fv complex: ∼54kD (SEC) or 67.2kD in static
light scattering (SLS); T117: ∼35kD (SEC) or 35.4kD (SLS); T117/Fv complex: ∼45kD
(SEC) or 45.2kD (SLS); and Fv: ∼17kD (SEC) or 26.2kD (SLS). The predicted Mr for
a T88 monomer is 8.4kD, demonstrating that T88 is tetrameric in solution and binds Fv
to form 2:2 complexes. The predicted Mr for a T117 monomer is 18.4kD, demonstrating
that T117 is dimeric in solution and binds Fv to form 1:1 complexes. Deviations between
estimates reflect the greater sensitivity of SEC to departures from sphericity.
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Epitope-scaffold affinities for MAb 4E10 were generally quite high. Antibody binding
affinity and kinetics were assessed by SPR in two formats: with 4E10 Fv in solution as
’analyte’ and epitope-scaffolds coupled to the sensor chip as ’ligand’ (to assess interactions
without avidity), and with 4E10 IgG captured on the chip and epitope-scaffold in solution
(to allow avidity). Examples of SPR data and fits are shown in Figure 2.3, and conditions
for each SPR experiment are given in Table 2.6 and 2.7. With epitope-scaffolds on the chip,
equilibrium dissociation constants (KD) ranged from 8 pM to 6 nM, and all epitope-scaffolds
bound 4E10 Fv more tightly than 4E10 peptides (KD = 10-20 nM [90, 64]), gp41 (KD =
32-35 nM [91]) or gp140 trimers from isolate SF162 (KD = 130 nM [64]). The range of KDs
was similar with epitope-scaffolds as analytes (22 pM to 3 nM). Monomeric epitope-scaffolds
exhibited similar KDs in both formats, while 120-fold tighter binding due to bivalent avidity
was detected for T88 (KD = 47 pM vs 5.6 nM) and 2.7-fold tighter binding was detected
for T176 (KD = 51 pM vs 140 pM), consistent with stoichiometry data. In both formats,
variations in both kon and koff contributed to variations in KD.
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Figure 2.3: SPR binding kinetics of 4E10 Fv/IgG with epitope-scaffolds or biotinylated
versions. Double reference-subtracted SPR responses in black with the corresponding kinetic
fits in red.
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Epitope-scaffolds showed a range of thermal stabilities assessed by circular dichroism
temperature melt analysis (Tm = 44
oC to Tm ≤ 100 oC ), though a majority (60%) were
very stable with Tm > 60 oC, and a large majority (80%) were stable with Tm > 50 oC.
2.4.3 Crystallographic analyses reveal high epitope structural mimicry by 4E10 epitope-
scaffolds
To assess epitope structural mimicry, crystal structures were determined for six different
epitope-scaffolds, four of unliganded epitope-scaffolds, and two of complexes with a 4E10
Fv construct biochemically validated elsewhere [64] (Figure 2.4). Crystallization conditions
are in Table 2.2; X-ray diffraction and refinement statistics are in Table 2.4; stereo images
of electron density maps are given in Figure 2.11.
31
Figure 2.4: Crystallographic analysis of 4E10 epitope-scaffolds.(A) Crystal structures of
six epitope-scaffolds (cyan tubes) superimposed with design models (red tubes), with the
epitope region colored yellow. Four structures are unliganded and two are complexed with
4E10 Fv W(H100A)A (H-chain, light-blue; L-chain, magenta). Resolution of structures was
2.3 (T18, PDB ID: 3LEF), 2.0 (T161, PDB ID: 3LF9), 1.9 (T117, PDB ID: 3LF6), 2.5
(T246, PDB ID: 3LG7), 2.65 (T88-Fv, PDB ID: 3LH2), and 2.8 (T93-Fv, PDB ID: 3LHP)
angstroms. (B) Epitope structure (yellow tubes and sticks) from each of the epitope-scaffold
crystal structures, superimposed with the 4E10 Fab-bound structure of a gp41 peptide
(green tube and sticks) from PDB ID: 2FX7[61]. Backbone RMSD values between epitope-
scaffold and peptide are indicated for each superposition.
32
The overall conformations of the epitope-scaffolds agreed well with design models in five
of six cases (Figure 2a), with backbone RMSD values between models and structures of
0.47, 0.50, 0.79, 1.14, and 1.26 A˚ for epitope-scaffolds T117, T18, T246, T93, and T161,
respectively. The structure of the T88-Fv complex revealed an unintended domain-swapped
dimer binding two Fv molecules, consistent with the 2:2 stoichiometry measured by SEC and
SLS. Nevertheless both T88-Fv complexes were very similar to the design model; ignoring
two residues that bridge the T88 dimer, backbone RMSD between the two Fv-monomer
complexes and the model were 0.6 A˚ and 0.5 A˚ respectively.
Most importantly, epitope mimicry was excellent in both Fv-bound and unbound epitope-
scaffolds (Figure 2.4B). Backbone RMSD between epitope-scaffold and the 4E10-bound con-
formation of the gp41 peptide [61], computed over epitope residues 672-680, was 0.99, 0.31,
0.99, and 1.1 A˚ for the unbound structures of T18, T117, T161, and T246 respectively,
0.16 A˚ for each monomer in the T88-Fv complex, and 0.31 A˚ in the T93-Fv complex. B-
factor analysis indicated that the epitope backbones were generally as well-ordered as the
epitope-scaffolds overall (Figure 2.5).
33
Figure 2.5: B-factor analysis of epitope-scaffolds. Crystal structures of the epitope scaffolds
are shown in cyan tubes with the epitope region in yellow; in epitope-scaffold complexes the
Fv H and L chains are shown as grey and magenta surfaces, respectively. The width of the
tube scales with the crystallographic B-factor (C-alpha atoms). Plots of C-alpha B-factors
versus residue number are shown in the right. In each case, data shown are representative
for all structures within the asymmetric unit.
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Side-chain mimicry was reduced in the unliganded structures (Figure 2.4B), but high
affinities for Fv indicated that appropriate side-chain conformers were attainable. Indeed,
inter-molecular contacts within the unliganded crystals stabilized different epitope side-
chain conformations at some positions (Figure 2.12). The T88-Fv and T93-Fv complexes
demonstrated precise mimicry at the side-chain level, with all-atom epitope RMSDs of 0.48
and 0.36 A˚ respectively; these complexes reproduced nearly all atomic contacts across the
bNAb-peptide interface [61, 62, 64] but made some additional contacts (Tables 2.5, 2.8, 2.9
and Figure 2.6).
Table 2.5: Buried surface areas of the epitope-scaffolds and the combined site of 4E10 Ab.
The buried surface areas were computed with the NACCESS [92] using a standard 1.4 A˚
radii water probe.
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Figure 2.6: Analysis of contact surfaces in the 4E10 Fab/gp41[61] and the 4e10 Fv/epitope-
scaffold complexes. Panels A-B show the 4E10 Fab/gp41 interface, looking through the
gp41 (tube/stick) toward the Fab surface (A) or toward the peptide surface from the Fab
(B). Panels C-D show the 4E10 Fv/T88 interface, looking through T88 toward the Fv (C)
or toward T88 from the Fv (D). Panels E-F show the 4E10 Fv/T93 interface, with views
analogous to those in C-D. The epitope segments of gp41, T88 and T93 are shown in yellow
tube (backbone) and stick (side chains), otherwise the T88 and T93 backbones are shown
in cyan tube. Atoms on the 4E10 epitope that contact the Fab or Fv are colored brown (B,
D, F), as are the corresponding contact atoms on the Fab or Fv (A, C, E). Atoms on the
Fv or epitope-scaffold involved in non-epitope contacts are colored white (C-F), except that
the epitope-scaffold side chains involved in non-epitope contacts are shown in cyan sticks
in C and E. 4E10 Fab or Fv H-chain is magenta, L-chain is grey. Most of the additional
contacts for T88 involved the domain-swapping ’bridge’ between the two monomers, and
the additional contacts for T93 were due to small conformational changes in the epitope-
scaffold and Fv compared to the design model. Such additional contacts might enhance
binding affinity for bNAb 4E10. Graphics were prepared with Pymol [93].
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2.4.4 Epitope-scaffolds as reagents reveal that neutralizing activity in HIV+ sera has 4E10-
like helical specificity while non-neutralizing anti-peptide sera does not
Sather et al.[66] recently found evidence for the presence of 4E10-like antibodies in the serum
of one HIV+ individual (”VC10028”). Support for this finding came primarily from the fact
that a 4E10 peptide, but not a scrambled 4E10 peptide, could inhibit a fraction of the neu-
tralizing activity of this serum in an in vitro neutralization assay. There are many potential
antibody epitopes on the 4E10 peptide, especially given that the peptide likely samples
many different conformations in solution, so the precise structural epitope(s) of the neutral-
izing antibodies in serum VC10028 could not be identified. Having demonstrated epitope
structural mimicry crystallographically (Figure 2.4), we employed 4E10 epitope-scaffolds as
reagents to determine whether the epitope conformation stabilized on the scaffolds was a
target of the cross-neutralizing antibodies in VC10028. Several epitope-scaffolds inhibited
the neutralizing activity of the sera (Figure 2.7A, B), but no inhibition was detected by a
’dead-epitope’ version of one scaffold (X36) in which the ’WF’ residues of the epitope were
mutated to ’ED’ (Figure 2.7B). These results demonstrated that neutralizing antibodies
targeting the helical epitope structure targeted by MAb 4E10 were present in the VC10028
sera.
In contrast, non-neutralizing rabbit sera elicited by a 4E10 peptide-KLH conjugate had
no significant affinity for any of several epitope-scaffolds tested, even though the peptide-
KLH sera bound avidly to 4E10 peptide itself (Figure 2.8A). This result demonstrated that
while the 4E10 peptide-KLH conjugate was immunogenic (one of three rabbits produced
peptide-specific antibodies), it did not elicit antibodies with structural specificity similar to
4E10. Indeed, comparison of peptide-KLH sera and MAb 4E10 binding to ALA-scanned
peptides (Figure 2.8B,C) confirms that the specificities are very different; MAb 4E10 binding
is greatly diminished by mutants W672A, F673A, T676A, and L679A that remove critical
contacts in the MAb/peptide crystal structure [61, 62, 64], but peptide-KLH sera binding to
those mutants is undiminished. Together, these results showed how epitope-scaffolds may
be useful as reagents to identify the presence or absence of precise structural specificities in
sera, and implied that epitope-scaffolds will be useful as bait to isolate antibodies targeting
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pre-defined structural epitopes.
Figure 2.7: 4E10 epitope-scaffolds inhibit neutralizing activity in HIV+ serum
VC10028[66].(A and B) Neutralization of JR-FL pseudovirus by serial dilutions of serum
VC10028 in the absence (open diamonds) or presence (solid shapes) of different 4E10
epitope-scaffolds at a concentration of 10 µg/mL epitope-scaffolds. All epitope-scaffolds
partially inhibit the neutralizing activity except a ’dead-epitope’ epitope-scaffold (X36,
blue inverted triangles in (B)). Data are representative of 3 separate experiments; error
bars represent means ± s.d.
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Figure 2.8: Structural specificities of bNAb 4E10 and anti-4E10-peptide rabbit serum are
dramatically different. (A) ELISA of anti-peptide serum binding to 4E10 peptide and
different epitope-scaffolds. Data representative of 2 experiments; error bars represent means
± s.d. (B) ELISA of anti-peptide serum binding to alanine-mutant 4E10 peptides. Data
representative of 3 experiments; error bars represent means ± s.d. (C) ELISA of bNAb
4E10 binding to alanine-mutant 4E10 peptides. Data representative of 3 experiments; error
bars represent means ± s.d.
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2.4.5 An epitope-scaffold elicited a structurally specific anti-epitope response
The fact that the 4E10-like antibodies in serum VC10028 had structural specificity similar
to MAb 4E10, while non-neutralizing antibodies in peptide-KLH sera did not, suggested
that neutralization via the 4E10 epitope may require antibodies with 4E10-like structural
specificity, and underscored the importance of testing epitope-scaffolds for their ability to
re-elicit such structural specificity. To this end we carried out immunization experiments
with specific endotoxin-free preparations of one 4E10 epitope-scaffold (T88). Two groups of
3 rabbits were immunized with T88, one group with QS21 as adjuvant, and the other with
PEI. One animal from each group developed antibodies that bound to HXB2 gp41, and this
gp41-reactivity was inhibited by wild-type 4E10 peptide, demonstrating specific reactivity
to the 4E10 epitope sequence (Figure 2.9). Further, the gp41-reactivity of the anti-T88
sera from these two rabbits was inhibited by three different epitope-scaffolds tested (T36,
T161, and T163) but not by a ’dead-epitope’ version of the T36 epitope-scaffold (Figure
2.9), demonstrating specific reactivity to the helical structure of the 4E10 epitope stabilized
on the scaffolds.
40
Figure 2.9: ELISA binding of anti-T88 rabbit sera to gp41 in presence of peptide and
epitope-scaffold competitors. Anti-T88 sera from two rabbits (blue, PEI adjuvant, five
immunizations; red, QS21 adjuvant, six immunizations) binds to gp41 (”Sera alone”).
Addition of peptide (”Sera+peptide”) or different scaffolds (”Sera+T161”, ”Sera+T163”,
”Sera+T36”) significantly reduces gp41-binding, but addition of a ’dead-epitope’ epitope-
scaffold (”Sera+X36”) does not. ELISA response of pre-bleed rabbit sera to gp41 was
subtracted from the data. Data were averaged from 2 or 4 experiments; error bars represent
means ± s.d.
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To assess the fine specificities of the anti-T88 sera and MAb 4E10 across the helical epi-
tope, we measured the binding of both sera and MAb to alanine-substituted 4E10 peptides
using a multiplexed Luminex assay [94]. The results are displayed in Figure 2.10 as ’relative
avidity’ in which the avidity for each ala-mutant is divided by the avidity of MAb 4E10 for
the wild-type peptide. A relative avidity significantly less than 1.0 indicates engagement
of a particular side-chain, as mutations to alanine should not detract from peptide helical
propensity. Strikingly, the results indicated that both T88 sera strongly engaged most epi-
tope side-chains transplanted onto the T88 scaffold, as relative avidities for ala-mutants at
gp41 positions 672-675 (WFDI) and L679 were less than 0.3 (p < 0.03 in all cases except
sera2 at I675 where relative avidity was less than 0.4 with p = 0.02). Two transplanted
epitope side-chains (T676 and W680) were engaged by one of the sera but not both; T676
relative avidity was 0.33 ± 0.28 for sera1 (engaged with relative avidity < 0.7, p = 0.02)
but 1.61 ± 0.33 for sera2, and W680 relative avidity was 0.49 ± 0.21 for sera2 (engaged
with relative avidity < 0.8, p = 0.01) but 0.74 ± 0.50 for sera1. Relative avidities for MAb
4E10 showed a similar overall pattern of side-chain engagement, except that MAb 4E10
did not engage I675 (relative avidity, 1.35 ± 0.18) and did strongly engage T676 (relative
avidity, 0.08 ± 0.05). The data for MAb 4E10 agreed with previous competitive ELISA
experiments [90] except at positions 675 and 680 where Luminex indicated no MAb engage-
ment but competitive ELISA [90] indicated moderate engagement. As expected, neither
of the two T88 sera nor MAb 4E10 had significantly altered avidity for ala-mutations of
gp41 residues N677 and W678 that are located on the opposite face of the helix from the
WFDITxxLW epitope of 4E10 and were not transplanted onto the T88 scaffold.
Gp41-specific IgG was purified from the sera and tested for fine specificity and neutral-
ization. The fine specificity of the gp41-specific IgG was consistent with that of the sera
in Figure ??. Neither the sera nor purified and concentrated anti-gp41 IgG reproducibly
neutralized HIV-1 in an in vitro neutralization assay (not shown).
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Figure 2.10: Luminex analysis of bNAb 4E10 and anti-T88 rabbit sera binding to ala-
scanned gp41 peptides on beads.Relative avidity for bNAb 4E10 (black) and two different
anti-T88 rabbit sera (blue, PEI adjuvant; red, QS21 adjuvant) quantifies the avidity of each
antibody-peptide or antisera-peptide pair relative to bNAb 4E10 binding to wild-type 4E10
peptide. Both anti-T88 antisera exhibit low relative avidity for mutants W672A, F673A,
D674A, I675A, and L679A, indicating that the antisera strongly engaged the 4E10 side-
chains at those positions on the helical epitope. Data were averaged from 5 experiments
each run in duplicate; error bars represent mean ± s.d.
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2.5 Discussion
Here, we presented a new technique, computational design of epitope-scaffolds, to design
immunogens that preserve the structure of a conserved epitope and expose that structure on
a variety of different protein scaffolds with different immunologic backgrounds. We trans-
planted a conserved HIV epitope to multiple non-HIV proteins, and succeeded to produce
small, stable, soluble proteins with high affinity for the target monoclonal (KDs < 1 nM).
Indeed, several epitope-scaffolds bound MAb 4E10 up to 1000-fold more strongly than cog-
nate peptide (KD ∼ 10 pM for epitope-scaffolds vs 10 nM for peptide). Crystal structures of
multiple scaffolds demonstrated near perfect mimicry of the desired epitope backbone con-
formation (RMSDs ≤ 1 A˚ ). We demonstrated the utility of epitope-scaffolds as serologic
reagents to identify the presence or absence of antibodies targeting specific structural epi-
topes; this diagnostic utility conceptually extends to the use of epitope-scaffolds as bait for
isolating such antibodies from libraries. Most importantly, we demonstrated that antibodies
specific for the helical structure and the conserved side-chains of the 4E10 epitope could
be elicited by immunization with one such 4E10 epitope-scaffold. In contrast, immuniza-
tion with peptide-KLH failed to elicit this desired specificity, and previous studies showed
that several different constructs competent for 4E10 binding failed to elicit any detectable
reactivity to the 4E10 linear sequence [67, 68, 89]. This example suggests the potential
power of epitope-scaffolding; with the technique described here, many types of contiguous
epitopes could be transplanted onto scaffolds for structural stabilization and immune pre-
sentation, and epitope-structure-specific immune responses might be further enhanced by
glycan- or PEG-masking of the scaffold, by multimeric, oriented display of epitope-scaffolds
on particles, by heterologous prime-boost immunizations, or combinations thereof. We also
note that the epitope-scaffold concept is not limited to scaffolding of antibody epitopes, it
could also prove useful to study, or design inhibitors for, peptide-protein and protein-protein
interactions.
To our knowledge, the antibodies elicited by T88 are the first induced by vaccination
to possess structural specificity highly similar to that of 4E10. This is an important ad-
vance for HIV vaccine design, because the helical specificity possessed by 4E10 and also
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the neutralizing sera in VC10028 [66] is likely necessary for neutralization via the 4E10
epitope. The T88 antisera elicited by these first-generation designs did not neutralize HIV,
however, indicating that helical specificity and the engagement of the conserved side-chains
of the 4E10 peptide epitope may not be sufficient. This result is consistent with recent
studies demonstrating that specific hydrophobic residues on the tip of the 4E10 CDRH3 are
required for maximum potency neutralization: alanine [95, 63, 64] and aspartic acid [63]
substitutions at the tip do not significantly reduce gp41 or epitope-peptide binding, but
they do reduce both lipid-binding [95, 63, 64] and the extraction of the epitope from the
membrane [64], either mechanism potentially contributing to neutralization potency. As
mentioned above, the tip of the 4E10 CDRH3 does not contact the peptide epitope used
as the basis of the design of these first-generation epitope-scaffolds [61, 62, 64]; further, no
contacts with the CDRH3 tip are seen in Fv 4E10/epitope-scaffold complex structures as
this was not a design criteria. Next-generation epitope-scaffolds incorporating higher-order
structural complementarity, such as viral membrane lipid structures, will be employed to
improve on this approach.
In summary, we introduced a computational methodology that allows the faithful trans-
plantation of conformational epitopes into distinct protein platforms, and demonstrated
that this leads to the appropriate stimulation of humoral responses to a conserved, but
intrinsically poorly immunogenic viral epitope. Epitope-scaffolds therefore expand the uni-
verse of immunogens available for vaccine research. For the case of 4E10, computationally
designed scaffolds can next be presented to the immune system in the context of lipid mem-
brane surfaces, in combination with specific adjuvants to elicit antibodies with expanded
recognition and neutralization properties.
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2.7.2 Electron density maps
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Figure 2.11: Stereo images of weighted 2Fobs-Fcalc electron density maps. Electron density
maps are shown as implemented in Refmac [84], contoured at 1.0σ, for the section corre-
sponding to the epitope, superimposed on the final structure (colored by atom type; chain
A shown in all cases). (A) residues 138-147 (GWFDITAYLW) in T18; (B) residues 15-24
(NWFDITGILW) in T88 (complexed with Fv); (C) residues 87-89 (NWFDISQSLW) in T93
(complexed with Fv); (D) residues 119-128 (NWFDITNVLW) in T117; (E) residues 77-86
(NWFDISQALW) in T161; (F) residues 43-52 (NWFDISQLLW) for T246. In all frames,
the N-terminus is at the bottom of the figure; in the some cases, residues could not be
confidently modeled because of the quality of the density and have been omitted from the
final structures. Figures were generated with Coot [83].
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Figure 2.12: Epitope side chain conformations are influenced by protein-protein interactions
within crystals of unliganded epitope-scaffolds. Shown on the left are epitope-scaffold mul-
timers in the crystal asymmetric unit (T117 dimer, T246 trimer) or epitope-scaffolds with
selected nearest neighbors generated using crystallographic symmetry (T18 dimer, T161
monomer). Shown on the right are zoomed-in and rotated views of the protein-protein
interactions involving the epitope, with side-chains shown in stick if they are part of the
epitope or are within 4.5 A˚ of the epitope. In all panels the epitope is shown in yellow.
T18 is dimeric in solution; the putative structure of the T18 dimer (cyan and purple) buries
706 A˚2 per monomer and exposes two epitopes, consistent with measured 2:2 stoichime-
try. Symmetry neighbors (brown, salmon) pack against the epitope on each monomer in
the dimer (burying 337 A˚2 on the cyan subunit and 275 A˚2 on the brown subunit). T117
and T246 are dimeric and trimeric in solution, respectively; both asymmetric units contain
the appropriate number of chains and bury sufficient area (1231 A˚2 per monomer by T117
and 1049 A˚2 per monomer by T246) to explain the solution multimer state. In both T117
and T246 multimers, the epitope is buried at the multimer interface, influencing epitope
sidechain conformations (different subunits colored in cyan, purple and brown). T161 is a
monomer in solution; the epitope packs against a neighbor (purple) in the crystal.
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Table 2.8: Hydrogen bonds and salt bridge interactions. The hydrogen bonds between the
complexes were assigned using the hbond application included in the CCP4 software package
(v.6.1)[82].
a Interactions listed in Cardoso et al. [61] not found in our analysis.
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Table 2.9: Van der Waals contacts in 2FX7 and epitope-scaffolds in complex with the 4E10
Fv. The interactions were assessed using the contact application included in the CCP4
software package(v. 6.1)[82].
a Interactions listed in Cardoso et al. [61] not found in our analysis.
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Chapter 3
COMPUTATIONAL PROTEIN DESIGN USING FLEXIBLE
BACKBONE REMODELING AND RESURFACING: CASE STUDIES
IN STRUCTURE-BASED ANTIGEN DESIGN
3.1 Abstract
Computational protein design has promise for vaccine design and other applications. We
previously transplanted the HIV 4E10 epitope onto non-HIV protein scaffolds for structural
stabilization and immune presentation. Here we developed two methods to optimize the
structure of an antigen flexible backbone remodeling and resurfacing and we applied those
methods to a 4E10 scaffold. In flexible backbone remodeling, an existing backbone segment
is replaced by a de novo designed segment of pre-specified length and secondary structure.
With remodeling we replaced a potentially immunodominant domain on the scaffold with a
helix-loop segment that made intimate contact to the protein core. All three domain trim
designs tested experimentally had improved thermal stability and similar binding affinity
for the 4E10 antibody compared to the parent scaffold. A crystal structure of one design
had 0.8 A˚ backbone RMSD to the computational model in the rebuilt region. Comparison
of parent and trimmed scaffold reactivity to anti-parent sera confirmed the deletion of an
immunodominant domain. In resurfacing, the surface of an antigen outside a target epitope
is redesigned to obtain variants that maintain only the target epitope. Resurfaced vari-
ants of two scaffolds were designed in which 50 positions amounting to 40% of the protein
sequences were mutated. Surface patch analyses indicated that most potential antibody
footprints outside the 4E10 epitope were altered. The resurfaced variants maintained ther-
mal stability and binding affinity. These results indicate that flexible backbone remodeling
and resurfacing are useful tools for antigen optimization and protein engineering generally.
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3.2 Introduction
Improvements in our ability to manipulate protein structure by design may facilitate de-
velopment of therapeutic molecules such as vaccines or minimized binding proteins, of in-
dustrially useful molecules such as enzymes, and of structurally-tailored reagents for re-
search. Computational protein design using ”fixed backbone” methods, in which amino
acid sequences are designed to stabilize pre-existing backbone conformations, has had many
successes including: thermo-stabilization[96, 97, 98, 99] and hyper-solubilization[100] of
proteins, design of metal[6] and small molecule binding proteins[101], novel enzymes [31,
30], enhancing or switching specificities at protein-protein[26, 24, 102, 103, 104], protein-
peptide[27] and protein-DNA[28] interfaces, enhancing antibody[105] and T cell receptor[106]
affinities for their targets, and stabilizing structural epitopes for immune presentation (Cor-
reia et al., in press; Ofek et al., in press).
More advanced ”flexible backbone” design methods that manipulate protein backbone
structure have even greater potential, as in principle they will allow protein designers max-
imum freedom to tailor protein structure and function to the needs of their applications.
”Flexible backbone” methods (reviewed in[107]) search both backbone conformation and
sequence space for low energy designs and have been employed less commonly than ”fixed
backbone” methods, owing to the increased computational cost and difficulties in develop-
ing appropriate sampling algorithms and accurate scoring functions. Nevertheless, several
design achievements have been made. Su et al. and Harbury et al. treated secondary struc-
tural elements as rigid objects and varied their relative distances and orientations through
algebraic supersecondary structure parametrization[108, 19, 19]. This approach, though
limited to folds that can be parametrized, led to the design of novel right-handed coiled-
coils, and the crystal structure of a tetrameric right-handed coiled-coil closely matched the
design model[19]. Kuhlman et al. pioneered a more general method for flexible backbone
design that involved iterating between fragment-based structure prediction and sequence
design[21]. The authors used this method to design a 93 residue α/β protein with a novel
fold; the protein was extremely thermostable and the model agreed with the crystal struc-
ture with a C-alpha RMSD of 1.2 A˚. A similar iterative strategy was employed to build and
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design three 10-residue loops onto the surface of tenascin, using loop modeling instead of
full protein structure prediction[48]. All three proteins were stable, and the crystal struc-
ture of one design showed close (sub-A˚ C-alpha RMSD) agreement between the designed
and crystallized loop conformations. Finally, the specificity of an enzyme was altered by
introducing a new active-site side chain in an appropriate position and then remodeling the
loop connecting that side chain to the rest of the protein using a combination of constrained
loop conformational sampling and sequence design[49]. Here too, crystallographic analysis
revealed excellent agreement (∼1 A˚ C-alpha RMSD) between designed and crystallized loop
conformations.
In the area of vaccine design, we recently presented a side chain grafting method for
transplanting contiguous conformational epitopes onto protein scaffolds for structural stabi-
lization and immune presentation (Figure 3.1). We demonstrated with two different epitopes
that computationally designed epitope-scaffolds can (i) stabilize epitope backbone confor-
mations with sub-A˚ backbone RMSD accuracy (ii) bind target antibodies with considerably
higher affinity than cognate peptide and (iii) elicit antibodies specific for the structure of
the transplanted epitope. Aside from their use as vaccine candidates, such epitope-scaffolds
may be useful tools to test various hypotheses concerning the relationship between structure
and immunogenicity.
Here, we sought to modify the structure of one such epitope-scaffold in two different
ways domain trimming by flexible backbone remodeling (Figure 3.1) and resurfacing with
the aim of significantly altering the structure and antigenic surface outside our epitope
of interest without harming the thermal stability, solubility, or high affinity for cognate
antibody. The long-term aim is to test whether molecules with such modifications can be
employed to heighten the immune reponse to the transplanted epitope.
Domain trimming was employed to eliminate potentially immunodominant, off-target
epitopes and required flexible backbone design. Here we present an efficient and generaliz-
able flexible backbone design procedure that allows one to trim a domain or segment and
in its place build and design a new segment of pre-specified length and secondary struc-
ture(s). To evaluate the performance of the protocol, three different trimmed constructs
were designed and experimentally characterized, and one crystal structure was determined.
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A detailed structural comparison of the design model versus crystal structure demonstrated
excellent agreement overall but also revealed subtle structural inaccuracies in the design
model; additional computational analysis was undertaken to understand these inaccuracies
and suggest improvements to the computational protocol. Finally, we tested the hypothesis
that domain trimming would eliminate distracting epitopes, by comparing the reactivity of
untrimmed and trimmed scaffolds to guinea pig sera elicited by the untrimmed scaffold.
Resurfacing was employed to redesign the surface of the epitope-scaffold outside the
epitope of interest without degrading stability, solubility, and high-affinity for the cog-
nate antibody. The purpose of resurfacing was to develop pairs of molecules with minimal
antigenic cross-reactivity except for the epitope of interest (here the 4E10 epitope); if suc-
cessful this approach could be expanded to develop larger sets (n-mers rather than pairs)
of resurfaced variants; development of such sets of minimally but specifically cross-reactive
antigens would allow future cocktail and prime-boost immunization experiments to test
whether resurfacing can be employed to focus immune responses to a particular structural
epitope. We have recently reported the design of resurfaced HIV gp120 molecules for use as
reagents to isolate novel HIV-neutralizing antibodies with unusual potency and breadth of
cross-reactivity[109]. In that work, the resurfacing design protocol took advantage of evolu-
tionary information that may not be available for most molecules. Here we present a simpler
and more general resurfacing protocol that favors mutations for amino acids with different
physical and chemical properties, and test it on an epitope-scaffold protein. Two resurfaced
variants were designed that modify approximately 40% of the overall protein sequence; a
computational surface patch analysis was developed to quantify the degree of antigenic
modification, and the stability, multimeric state, and binding affinity of the molecules was
assessed.
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Figure 3.1: Design stages of a trimmed epitope-scaffold.The crystal structure of the 4E10
epitope in complex with the antibody (PDB ID: 2FX7) was the starting point for the design
of epitope-scaffolds using the side chain grafting procedure. The initial epitope-scaffold was
further optimized by trimming a domain unnecessary for epitope recognition.
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3.3 Materials and Methods
3.3.1 Flexible backbone remodeling
The computational protocol to rebuild and design de novo backbone segments were com-
prised of five stages. In stage (i) length and secondary structure were defined for the de
novo segment. In this particular problem, 10 different combinations of helix/loop lengths
were attempted. In stage (ii) 500 new backbone segments were generated using an ab ini-
tio fragment insertion protocol as described by Simon et al. [22]. The fragments used
for the loop building stage were selected wholly based upon secondary structure assign-
ment; no sequence information was considered. To maintain proper polypeptide chain con-
nectivity, cyclic-coordinate descent (CCD) chain closure[110] was used within the rebuilt
region[38, 39]. Residue identities at the positions within helix and loop secondary structure
were pre-defined as alanine and glycine, respectively. Each new configuration of the rebuilt
loop was evaluated according to a Metropolis criterion based on the total energy of the
protein computed with a low resolution energy function[111]. The final combinations of sec-
ondary structure linker lengths were selected in order to exclude linkers presenting kinked
helices or extra long loop segments. From the 10 initial combinations of helix/loop lengths,
two different segment lengths were selected to proceed on the design stage: length 16 with
secondary structure (HHHHHHHHHHHHLLLL), and length 17 with one additional loop
residue yielding secondary structure (HHHHHHHHHHHHLLLLL). In stage (iii) the remod-
eled segment and neighboring residues were designed with standard RosettaDesign[15] in
order to find sequences that maximally stabilize the conformation of the newly remodeled
region. For design positions, all amino acids except cysteine were allowed during the design
process. The best 3 scoring designs from each of the initial backbones were relaxed using
a full-atom energy function[111]. In stage (iv), filtering based on structural features was
performed. From the resulting 1500 designs output in stage (iii), all designs with buried
polar atoms were dismissed. This filtering resulted in 423 and 59 designs remaining for the
linker lengths 16 and 17, respectively. A second filtering step was performed using a double
criteria where all the designs ranked within the best 20% by full-atom energy and packing
score[112] were selected. Final designs for experimental characterization were selected from
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the remaining pool, and were the two best ranking designs by full-atom energy for linker
length 16 and the single best ranking design for linker length 17. In the final stage (v)
to optimize solubility, a few hydrophobics in surface patches were manually redesigned to
alanine, lysine, or arginine. The Rosetta design algorithm is not yet optimized for solubility
so restricted design on the surfaces of designed proteins is often necessary. The manual
mutations were as follows: T72 (I36A, I37A, I40A, Y41K), T81 (A44R), T93 (L33K, I36A,
L37A, I40K).
3.3.2 Structure prediction
The computational model for the trimmed design T93 was the starting point for the loop re-
lax simulations[39]. NNMAKE fragments[111] were generated with the secondary structure
assignment observed in the actual crystal structure of T93. The segment for the prediction
calculations was 27 residues long, comprising residue 31 to 56 as per crystal structure num-
bering. 20000 models were generated and compared with the crystal structure in terms of
structural and energetic convergence. Two different types of refinement (CCD-refine and
all-atom relax) were performed on the 100 lowest energy structures generated by the loop
relax simulation, to sample low energy conformations more finely. CCD-refine[110], which is
essentially the loop modeling procedure described in [39] but lacking the fragment insertion
stage, sampled new conformations for a section of the protein around the rebuilt region.
All-atom relax[111] allowed small moves in backbone torsion angles and cycles of repacking
followed by minimization of side chain rotamers over the entire protein. The relaxed crystal
structure ensemble was generated with the all-atom relax procedure.
3.3.3 Resurfacing
Surface residues were selected based on visual inspection excluding the epitope-antibody in-
terface. The resurfacing design calculations were carried with standard RosettaDesign[15].
The amino acids allowed in each of the selected surface positions were ADEGKMNQRST.
1000 models were generated for each starting structure and the final designs to be experi-
mentally characterized were selected according to a sequence difference score (SEQ DIFF),
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in which preference was given to designs with least degree of sequence identity to the starting
sequence. The sequence difference score was composed of two terms and it was computed as
follows: SEQ DIFF = FLIP SCORE + (0.5 x NEG POL SCORE). The amino acids were
grouped according to their chemical properties: negatives (D and E), positives (R and K),
polars (N and Q) and other (A, F, G, H, I, L, M, P, S, T, V, W, Y). The FLIP SCORE
was 1 in case there was one of two scenarios: a) sequence change from negative or polar to
positive or vice-versa; b) sequence change from group ’other’ to any of the remaining groups
or vice-versa. The NEG POL SCORE was 1 if there was a sequence change from negative
to polar or vice-versa.
3.3.4 Surface patch analysis
The surface patch analysis was performed by placing spheres centered on each of the exposed
C-alpha atoms of the crystal structure or computational models under analysis. A patch was
composed of all solvent exposed residues with C-alpha atoms contained within the sphere.
By definition, any given residue was allowed to belong to multiple patches. Residues were
defined as solvent exposed if more than 30% of the side chain surface area was exposed to
solvent according to NACCESS[92]. The sphere radius was 11 A˚, yielding an area of 380 A˚2
on the largest cross section of the sphere. This cross section aimed to be a low-resolution
approximation of a minimal antibody footprint. Once patches were defined in an initial
molecule, each patch was compared to its corresponding patch in the resurfaced variant and
the percentage of mutations within each given patch was computed.
3.3.5 Experimental methods
Protein expression, purification, and biophysical characterization were carried out as de-
scribed in Correia et al. Experimental conditions for the SPR experiments are presented in
Table 3.3. ELISA experiments were performed as described in Correia et al.
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3.4 Results
3.4.1 Computational flexible backbone remodeling
To heighten the immune response to a particular epitope on an antigen, one rational strategy
is to minimize the size of the antigen and eliminate other potentially immunogenic domains.
Previously, we designed a panel of epitope-scaffolds for the conserved HIV 4E10 epitope by
the side chain grafting method (Correia et al., in press), with the goal of eliciting antibodies
specific for the structurally stabilized 4E10 epitope. One particular epitope-scaffold was
based on a mutant of the E. coli Ribosome Recycling Factor (RRF) (PDB code: 1ISE,
chain A) and was a two-domain protein with the conserved RRF fold[113] that includes
a three-helix bundle and a globular beta-alpha-beta sandwich, with an overall ”L” shape.
This epitope-scaffold (T36) had an extremely high affinity for the monoclonal antibody 4E10
(Table 3.1), so we decided to minimize its size in an effort to optimize the immunogenicity
of the transplanted epitope. We had transplanted the 4E10 epitope to one end of the
three-helix bundle, and we sought to remove the globular domain without compromising
the thermal stability or 4E10 binding affinity of the molecule. In particular, we aimed to
replace the alpha-beta globular domain with a single helix followed by a short loop, in which
the helix-loop segment would make contacts with the protein core promoting structural
integrity and stability.
To meet this goal, we devised an efficient and general computational protocol involving
flexible backbone design to remove the extraneous domain and remodel the region with
segments of pre-specified length and secondary structure. Briefly, the protocol (Figure
3.2) was composed of six main stages: (i) selection of one or more lengths for the new
segment and specification of the secondary structure at each position in the segment, (ii) de
novo building of the segment, where backbone conformations were sampled by insertion of
fragments that satisfy the desired secondary structure(s), (iii) sequence design in which low
energy amino acid sequences were selected for each backbone conformation, (iv) all-atom
relaxation in which each structure was optimized with small backbone perturbations and
side chain rotamer packing and minimization, (v) filtering in which designs were selected
based on buried unsatisfied polar atoms, packing and Rosetta full-atom energy, and (vi)
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solubility optimization in which hydrophobic residues in surface patches were mutated to
polars or alanine. Protocol details are given in Materials and Methods. Three designs (T72,
T81, and T93) were selected for experimental characterization (Figure 3.3); two had a de
novo segment with length 16 (T72 and T93) and the third had length 17 with one more
residue in the loop connection (T81). The selected computational designs had significantly
different sequences in the remodeled segment and in neighboring positions (Table 3.2 and
Figure 3.3).
Figure 3.2: Overview of the computational protocol to build and design new segments of
backbone.
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Figure 3.3: Computational models of trimmed scaffolds selected for experimental charac-
terization. Backbone is shown in tube representation and core side chains of the redesigned
region are shown in sticks representation.
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Table 3.1: Characterization of the solution properties of the trimmed and resurfaced epitope-
scaffolds.
1 Epitope-scaffold was immobilized by biotinylation and capture on SA chip.
2 4E10 IgG was captured by amine-coupled anti-human IgG.
For all reported values, standard error is ≤±3 of the last significant figure.
Table 3.2: Structural and sequence features of selected computational designs selected for
experimental characterization. Residues in the core are colored in red.
aLengths off the secondary structure elements used in the computational procedure
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3.4.2 Biophysical characterization of the computational designs
Design of well-folded, soluble, stable and functional proteins based on flexible backbone
design remains a major challenge due to inaccuracies in energy functions and difficulties
in sampling protein conformational spaces. To evaluate the performance of the flexible
backbone protocol presented here, we subjected several of our computationally designed
proteins to biophysical characterization. Solution multimeric states were determined using
size exclusion chromatography (SEC) and static light scattering (SLS), thermal melting
points were assessed by circular dichroism (CD) melting analysis, and dissociation constants
(KD) and kinetic constants (kon, koff ) for antibody binding were determined using SPR
(see Materials and Methods). This biophysical data is collected in Table 3.1 for the parent
scaffold (T36) and the three trimmed scaffolds illustrated in Figure 3.3 (T72, T81, and
T93).
All three domain trimmed variants (T72, T81, T93) were monodisperse and monomeric
according to SEC-SLS analysis, as was the parent (T36). The thermal stabilities of the
domain trimmed scaffolds (T72, T81 and T93) were 70, 79, and 79 oC, respectively, consid-
erably higher than the parent with Tm = 44
oC (Figure 3.4).
Dissociation and kinetic constants, were evaluated by SPR in two formats: (I) epitope-
scaffold amine-coupled to the SPR chip and 4E10 scFv flowing as analyte; (II) epitope-
scaffold as analyte and 4E10 IgG captured by amine-coupled anti-human IgG. SPR sensor-
grams are shown in Figure 3.5. The two formats produced similar results in that nearly
all the individual KD, kon, and koff fit values agreed within a factor of 3 measured in one
format or the other. The parent scaffold (T36) bound 4E10 very tightly, with KD = 14 ±
3 and 44 ± 3 pM as measured in formats I and II, respectively. Two of the three trimmed
scaffolds (T81 and T93) bound 4E10 with similar or marginally better dissociation constants
than the parent, with a range of KD = 27.5 to 33 pM in both formats for T81 and T93. The
ranges of on-rates ( kon = (2.82 - 6.98) x 10
6 M−1 s−1 ) and off-rates ( koff = (5.23 - 9.30)
x 10−5 s−1) for these two trimmed scaffolds were similar to the parent ranges (kon = (1.95
- 5.89) x 106 M−1 s−1 and kof f = (5.23 - 9.30) x 10−5 s−1). The other trimmed scaffold
(T72) had similar KD as the parent scaffold when assessed in format II (KD = 17.7 pM),
67
Figure 3.4: Computational designs showed improved thermal stabilities compared to the
parent epitope-scaffold. Thermal stabilities were assessed by circular dichroism.
but had a slower on-rate and faster off-rate in format I compared to format II leading to a
higher KD value in format I (228 pM). The reason for this discrepancy is unclear, however
the essential conclusion remains that the trimmed scaffolds generally maintained the high
affinity of the parent.
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Figure 3.5: SPR binding kinetics of 4E10 Fv/IgG with epitope-scaffolds. Double reference-
subtracted SPR responses are in black with the corresponding kinetic fits in red. (A)
Biotin-T72 coupled to chip. (B) T72, 4E10 IgG captured. (C) Biotin-T81 coupled to the
chip. (D) T81, 4E10 IgG captured. (E) Biotin-T345 coupled to the chip. (F) T345, 4E10
IgG captured. (G) Biotin-T353 coupled to the chip. (H) T353, 4E10 IgG captured. (I)
Biotin-T355 coupled to the chip. (J) T355, 4E10 IgG captured.
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3.4.3 Structural analysis of a computational design
To assess the atomic accuracy of the computational designs, we sought to compare our
design models to crystal structures of the designs. Crystallization trials were performed on
the three trimmed variants (T72, T81, and T93), both unliganded and in complex with 4E10
scFv. A crystal structure of T93 in complex with scFv 4E10 (see Figure 3.6A) was solved at
2.8 A˚ resolution, and a comparison of the structure and the design model in the region of the
transplanted 4E10 epitope has been reported (Correia et al., in press). Here, we compare
the design model and crystal structure at the other end of the three-helix bundle (Figure
3.3), in the region where the globular domain was replaced with a helix-loop segment by
flexible backbone design as described above.
Overall, the T93 computational model is in close agreement with the crystal structure,
with a RMSD of 1.1 A˚ over the backbone atoms (N, CA, C, and O) of the epitope-scaffold
(Figure 3.6B). Within the remodeled segment alone (residues 27 to 45 in 3LHP numbering),
the computational model and the crystal structure are also in very close agreement, with a
backbone RMSD of 0.8 A˚.
Side chain rotamers (chi1, chi2) were correctly predicted for 7 out of 11 non-alanine side
chains that constitute the core (side chain surface area solvent accessible < 30%) of the
remodeled region (see examples in Figure 3.6C), but incorrectly predicted for four such side
chains. Two of the incorrectly predicted side chains were errors in Leu chi2 angles that
caused relatively minor alterations in packing interactions with neighboring side chains, but
the other two mistakes were errors in the chi1 angle of a Phe (F34) and the chi2 angle of a
Trp (W51) that caused significant differences in packing between the design and the crystal
structure (Figure 3.6D).
Though the design was quite successful overall, we sought to understand the origin of
these rotamer errors in order to gain insight on how to further optimize our computational
protocol. Structural comparison of the design and crystal structure identified two potential
aspects of the design model backbone that could have led to the incorrect rotamers for F34
and W51. First, the design model has a different backbone conformation in the loop of the
remodeled region that prevents W51 from adopting the rotamer in the crystal structure a
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Figure 3.6: Structural comparison of the crystal structure with the computational model
for the T93 trimmed epitope-scaffold. (A) Crystal structure of a trimmed epitope-scaffold
in complex with the 4E10 scFv. The backbones are shown in ribbons, T93 is colored in red
and the 4E10 scFv is colored in blue. (B) Backbone superposition of T93 crystal structure
and computational model. T93 crystal structure is colored in red and the computational
model is colored in green and yellow in the remodeled region. (C) Three examples of core
side chains accurately predicted in the computational model (M116, W119, and V38). (D)
The three notable core side chains inaccurately predicted in the computational model (F34,
P43, and W51).
proline residue in the loop (P43) points outward in the crystal structure and allows W51
to pack into the core adjacent to P43 (Figure 3.6D), while in the design model P35 points
inward and sterically prevents W51 from packing into the core (Figures 3.6D and 3.7).
Second, the design model has a smaller spacing between helices one and two in the region
of F34 and W51 that prevents F34 from adopting the rotamer in the crystal structure the
8.04 A˚ distance between the C-beta of F34 and the C-alpha of W51 in the crystal structure
allows F34 to pack adjacent to W51 (Figure 3.6D) but the shorter distance (7.12 A˚) in the
design model sterically prevents F34 from assuming that rotamer (Figures 3.6D and 3.7).
Thus, small inaccuracies in the backbone conformation (within the 0.7 A˚ backbone RMSD
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from the crystal structure) were likely sufficient to enforce two packing errors.
Figure 3.7: Some side chain rotamers in the T93 crystal structure are incompatible with the
backbone conformation of the initial computational design model. Side chains in magenta
were observed in the crystal structure and side chains in yellow and green were predicted
in the computational design. (A) Crystal structure of T93 showing the F34, P43, W51 in
sphere representation. (B) Computational model with side chains inaccurately predicted
(F34, P43, W51) shown in sticks and spheres. (C) Native rotamer of tryptophan (W51)
is incompatible with the proline (P43) conformation observed in the computational model.
(D) Steric clash between the native phenylalanine (F34) and tryptophan (W51) from the
design. Additionally, steric clashes occur between native F54 and both the C-alpha and C-
beta atoms of the neighboring helix (helix from W51), showing that the distance or relative
orientation or both are not exactly the same in the model and the crystal structure.
3.4.4 Analysis of the computational protocol
The above observations indicate that in order to improve flexible backbone computational
design methods, it is important to understand the origin of even small errors such as in-
correct helix-helix spacing, conformation of the proline, and the two incorrect side chain
predictions discussed above. The goal of such analysis is to understand how to modify the
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design procedure to avoid such inaccuracies in the future. Such errors can generally arise
from imperfect energy functions, incomplete conformational sampling, or both. One hint
that the errors noted above were due to incomplete sampling came from our observation
that the Rosetta all-atom energy was considerably lower for the relaxed crystal structure
than for the design model. This implied that the Rosetta energy function was capable of
discriminating between similar backbones (0.7 A˚ RMSD) with only a few side chain packing
differences.
To further investigate the hypothesis that the above inaccuracies were due to incom-
plete sampling, we used Rosetta to generate ensembles of low energy conformations for the
designed scaffold and assessed whether finer sampling could recapitulate the conformation
and low energy of the crystal structure. We generated three ensembles with different com-
binations of methods that differed in both the scope (local vs global) and amplitude of
their sampling across the protein. The first ensemble was created by a Rosetta loop relax
protocol [39] that aggressively sampled conformations for the remodeled region only (Fig-
ure 3.9). The second ensemble was generated by a loop refine protocol (Cyclic Coordinate
Descent (CCD)[110, 39] refine) starting from the 100 lowest energy models in first ensem-
ble, but the scope of sampling was expanded to include residues neighboring the remodeled
region (Figure 3.9B). The third ensemble, with the greatest scope of sampling, also derived
from the 100 lowest energy models in the first ensemble but was generated by an all-atom
relaxation of side chains and backbone torsions, allowing small movements over the entire
model[111, 77] (Figure 3.9C).
Remarkably, the third ensemble did produce models with low energies and conforma-
tional features (helix-helix distance, F34 and W51 rotamers, P43 conformation) closely
matching the crystal structure (Figures 3.9C, 3.10 and S4), while the other ensembles never
produced all of these features in a single model. This set of simulations confirms that
the small errors in the original design model were indeed due to incomplete sampling, and
demonstrates that the Rosetta energy function is capable of discriminating subtle structural
features.
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Figure 3.9: Structural prediction of the
de novo remodeled segment in T93.
RMSDpartial is the backbone RMSD to the
T93 crystal structure, computed over the
remodeled region (residues 25-55 in 3LHP
numbering) and at positions on the third he-
lix in close contact to the remodeled region
(residues 109-123). Energypartial is the full-
atom energy computed over the same region
where the RMSD was measured. The partial
energy is computed to dismiss any structural
differences caused by the co-crystallization
of T93 with the 4E10 scFv. (A) Energy ver-
sus RMSD for loop relax models of the T93
design (blue) and for the all-atom relaxed
T93 crystal structure (magenta). Both sim-
ulations achieve low RMSD but the relaxed
crystal structure is considerably lower in en-
ergy. Inset: The moveable region for loop
relax is indicated by blue spheres and the re-
gion over which RMSDpartial was measured
is indicated by green tube. The entire crys-
tal structure was all-atom relaxed. (B) En-
ergy versus RMSD as in (A) but also in-
cluding results for CCD-refine (yellow) of
the lowest energy models from loop-relax
(cyan). The lowest energy CCD-refine mod-
els are similar in energy to the all-atom re-
laxed crystal structure. Inset: The move-
able region for CCD-refine (residues 23-65
and 104-122 using 3LHP numbering, larger
than the moveable region for loop relax) is
indicated by yellow spheres. (C) Energy
versus RMSD as in (A) but also including
results for all-atom relax (red) of the low-
est energy models from loop-relax (cyan).
The energy distribution of these all-atom re-
laxed models is similar to the distribution
for the all-atom relaxed crystal structure.
(D) Structural superposition of a low en-
ergy and low RMSD all-atom relaxed design
(red) with the lowest energy relaxed crystal
structure of T93 (magenta). Side chain ro-
tamers inaccurately predicted in the initial
computational design but successfully recov-
ered after additional conformational sam-
pling (F34, P43, W51) are shown in sticks.
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Figure 3.10: Distributions of side chain RMSDs between native rotamers in T93 crystal
structure and models generated by several prediction protocols. The residues shown were
inaccurately predicted in the initial computational design: F34, P43 and W51 (3LHP num-
bering). Methods used to generate models are described in the Material and Methods
section.
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Figure 3.11: Dependency between helix distance and side chain conformation. The x-axis
shows the distance between helix 1 (C-beta, F34) and helix 2 (C-alpha, W51) on the bundle;
the y-axis shows the side chain RMSD of F34 between the native rotamer and the rotamers
observed in models generated by different prediction-refinement protocols. The color scale
applied to the dots represents the energy of the residue F34 according to Rosettas full atom
scoring function. Overall, the different simulations show that the correct rotamer (low
RMSD on the y axis) is only sampled if the helix-helix distance is very close to 8 A˚. When
the correct conformation is sampled it is recognized as an energy minimum.
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3.4.5 Domain trimming eliminates ”distracting” epitopes
Having confirmed the biophysical properties of three trimmed scaffolds (T72 ,T81, and T93)
and confirmed the atomic structure of one (T93), we sought to test our original hypothesis
that the globular domain of the parent scaffold T36 was immunodominant. For this test,
we compared the binding of the guinea pig T36 antisera to T36 and to one of the trimmed
scaffolds. As shown in Figure 3.12, the T36 antisera from all three of the T36-immunized
animals reacted strongly with T36 itself, but the reactivity to the trimmed scaffold T72 was
significantly (4.5-fold) decreased.
Figure 3.12: ELISA reactivity of the trimmed T93 scaffold to guinea pig sera elicited by
the parent epitope-scaffold T36. The pre-bleed measurements were subtracted to account
for the endogenous response of the animals.
3.4.6 Resurfacing
Above we have addressed flexible backbone remodeling of an antigen - a 4E10 epitope
scaffold - in order to remove a potentially immunodominant domain. Here, we address
a different method in an attempt to alter the antigenic properties of a given molecule,
namely resurfacing. Resurfacing aims to change most or all of the exposed residues on
the surface of a protein, keeping only a functional site or epitope of interest unchanged.
Potential applications of resurfacing might include (A) improving solubility or stability,
or altering the multimerization state of a protein, or (B) developing variants of a given
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antigen that contain no cross-reactive epitopes except for a particular epitope of interest,
or both. The achievement of (B) in particular could provide molecular reagents useful for
probing antibody specificities in sera or isolating monoclonal antibodies with particular
specificities, and could also provide opportunities for novel immunization schemes involving
cocktails or heterologous prime-boost of resurfaced antigens. Epitope-scaffolds are useful
model systems to investigate this strategy since they are small, stable and bind with high
affinities to the target antibodies. In terms of design difficulty, resurfacing is less aggressive
than remodeling/domain trimming, because resurfacing requires only fixed backbone design
of surface-exposed side chains; however, altering a large fraction of a protein surface implies
mutating a significant fraction of the protein sequence and can potentially impact expression,
stability, solubility and binding affinity.
Lawrence et al. previously reported a method to redesign the surface of proteins to in-
crease their solubility and stability by greatly increasing the net charge (”super charging”)[100].
T72, T81, and T93 were neutral or slightly positively charged (net charges +2, 0, and +2,
respectively). As a test of super-charging, we redesigned the surface of T72 to reach large
positive (+26) and negative (-22) net charges, but neither of those variants could be puri-
fied. Based on those results we decided to limit our resurfacing designs to maintain similar
net charge.
As a first step to evaluate the viability of the resurfacing strategy, T93 and a further
remodeled variant of T93 (T345) were resurfaced while retaining the 4E10 epitope, and
experimentally characterized. T345 was designed using flexible backbone remodeling to
both shorten a loop leading into the 4E10 epitope and to lengthen a helix underneath
the epitope, both aspects of the design attempting to further stabilize the antibody-bound
conformation of the epitope. T345 had marginally improved stability over T93, and similar
binding affinity and kinetics to T93, but was a mixed monomer/dimer in solution whereas
T93 was a pure monomer (see Table 3.1).
T93 and T345 surfaces outside the 4E10 epitope were mutated using RosettaDesign
in conjunction with a customized score to favor mutations to amino acids with distinct
chemical properties and maximize the difference in terms of the number of side chain atoms
(see methods). The resulting ”resurfaced” epitope-scaffolds were T353 (derived from T93),
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and T355 (derived from T345). T353 and T355 had 49 and 48 surface residue mutations,
respectively, meaning that 42% and 40% of each protein was mutated (Figure 3.13). In both
the designs approximately 45% of the mutations were from charged to charged amino-acids,
25% were apolar to charged, and roughly 15% were charged to polar (Figure S5). The
theoretical net charge of the resurfaced designs was not allowed to deviate far from T93;
the theoretical net charges of T353 and T355 were +2 and +3, respectively.
Figure 3.13: Mutations on the resurfaced variants of the epitope-scaffolds. Epitope is colored
in yellow, the unchanged residues are colored in blue and the surface mutated residues are
shown in red.
A surface patch analysis was performed to quantify the degree of antigenic change that
was imposed on the molecules by resurfacing. The surface of each parent molecule was
divided into patches and then compared to the corresponding patches on resurfaced variants.
Each patch was defined as the solvent-exposed amino acids enclosed within a sphere of radius
11 A˚ centered on the C-alpha atom of a surface-exposed residue; patches were defined
for spheres centered on every surface-exposed position (Figure 3.15A). The sphere radius
was chosen so that the enclosed surface area (∼400 A˚2) would approximate a minimal
antibody binding footprint [114]. The aim of the patch analysis was to assess the number
of mutations in each of the patches and identify regions of the surface that might require
additional mutations. Ideally only patches centered on epitope residues would have few or
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Figure 3.14: Categorization of the types of mutations performed in the Resurfacing proce-
dure. The two most prevalent types of mutations employed were mutations from apolar to
charged amino acids and from charged to another charged amino acid.
no mutations in the resurfaced variants compared to the parent molecules (Figure 3.15 -
see sphere enclosing yellow epitope). For T353, the resurfaced variant of T93, 48 out of 78
patches presented 50% or less of sequence identity, and the statistics were approximately
the same for T355 and its parent T345 (Figure 3.15B,C).
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Figure 3.15: Surface patch analysis. (A) Schematic of the surface patch analysis procedure.
Spheres in light blue define patches of surface residues that are then compared with the
corresponding patch on the resurfaced variant; the number of mutations performed at each
patch is computed. Dark blue spheres represent examples of exposed residues that were
centers of patches and red spheres represent residues that belong to a given patch. Only
residues with side chain solvent exposure greater then 30% (according to NACCESS) were
considered as part of a patch. (B) Percent of residues mutated within each patch of the
resurfaced variant T345 relative to its initial design T93. (C) Percent of residues mutated
within each patch of the resurfaced variant T355 relative to its initial design T353.
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The biophysical properties of the resurfaced designs were generally consistent with the
parent molecules. The resurfaced designs had improved thermal stabilities, with T353
having a Tm > 95
oC compared to Tm = 79
oC for the parent T93, and T355 having a
Tm = 90
o compared to 84 o for the parent T345. The effect of resurfacing on multimeric
state was mixed; T353 was a mixed monomer/dimer in solution even though the parent
T93 was a pure monomer; on the other hand T355 was a pure monomer in solution while
the parent T345 was a mixed monomer/dimer. We do know that the 4E10 epitope itself
can mediate dimerization but that other scaffold-scaffold interactions can modulate this
tendency (Correia et al., in press, Xu et al. in preparation), and so it is possible that
these changes in multimer state are due to such modulations in the propensity for epitope-
mediated dimerization. The resurfaced designs maintained high affinity for 4E10, though
the dissociation constant for T353 was increased 70-fold (KD = 522 pM compared to 7.49
pM for the parent T93) and the dissociation constant for T355 was increased 3-fold (KD =
165 pM compared to 50.6 pM for the parent T345).
3.5 Discussion
Here we presented an efficient and general method for remodeling of segments of a protein,
in which an existing segment is replaced by a de novo designed segment of pre-specified
secondary structure. Given a high-resolution protein structure and a segment that is to
be replaced, the method entails pre-specifying the length and secondary structure of the
new segment, de novo building an ensemble of backbone conformations for the segment
in the new protein, fixed backbone design of the segment and neighboring positions in
each member of the ensemble, and filtering the resulting models by various energetic and
structural criteria. We also presented a simple method for resurfacing a protein, in which
the entire exposed surface of a protein outside a functional site is subjected to redesign. We
tested these methods on an epitope-scaffold, a scaffold protein onto which we had previously
transplanted the HIV 4E10 conserved neutralization epitope, and we presented biophysical
and structural analysis of remodeled and resurfaced variants of the initial epitope-scaffold.
In our test of the remodeling method, the initial scaffold had the ”L”-shaped RRF fold
with a three-helix bundle and an internal 77 residue globular domain connected to the
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bundle by two flexible linkers; by de novo design, we replaced the globular domain with a
16 or 17 residue helix-loop linker that made intimate contact to the core of the remaining
three-helix bundle. Three designs with significantly different sequences were purified from
E. coli ; all had markedly improved thermal stability over the parent scaffold (Tm improved
from 44 oC to 70-79 oC), all were monomeric in solution like the parent, and all had similar
or marginally improved binding affinity for the 4E10 antibody. Crystallographic analysis of
one of the trimmed scaffolds in complex with 4E10 demonstrated close agreement between
the design model and the crystal structure in the region that was remodeled (backbone
RMSD = 0.8 A˚); the remodeling procedure is therefore capable of atomic-level accuracy
in design of novel protein segments. Finally, we demonstrated that the globular domain
deletion from the scaffold succeeded to eliminate an immunodominant domain, because
polyclonal sera elicited by the parent scaffold cross-reacted only weakly to the trimmed
scaffold.
Despite the overall success of this design, our comparison of the crystal structure to its
corresponding design model revealed several subtle differences and our follow-up analysis
(a) showed that the Rosetta energy function recognized the crystal structure as lower in
energy than the design model and (b) implied that increased conformational sampling in
our design protocol would have avoided the observed inaccuracies. There are two aspects of
the protocol that we will improve. First, the initial generation of backbone conformations
using the Rosetta centroid energy function is susceptible to building overly compact protein
structures[115, 111]; here we may have accentuated that problem by using alanine centroids
during de novo linker building. Our observation of overly tight helix-helix spacing (and the
effect of that tight spacing on side chain packing) within the remodeled region highlights
that this aspect of the protocol should be improved. Second, the success of the full-atom
optimization protocol in recapitulating key structural features of the crystal structure absent
in the design model indicates that addition of a full-atom optimization stage in between the
current design and filtering stages would be beneficial.
Our tests of the resurfacing method started with two of the trimmed scaffolds that we
had designed by remodeling. Resurfacing was achieved by fixed-backbone protein design of
surface exposed residues using RosettaDesign and selecting design sequences with the least
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similarity to the parent as judged by a ”sequence difference” score. Two resurfaced proteins
were designed, one for each of two parent trimmed scaffolds, in which 50 residues (40% of
the protein sequences) were mutated. A patch analysis was developed to assess whether all
potential antibody epitopes had been altered; patch analysis of the two resurfaced variants
indicated that most but not all epitopes had been heavily modified. The resurfaced proteins
had moderately improved thermal stabilities but also larger dissociation constants for the
target antibody 4E10.
These results indicate that de novo remodeling, in particular trimming, can be employed
to minimize therapeutic proteins or other proteins of interest without sacrificing stability,
solubility, or functional activity (e.g. binding). While trimming of loops and domains has
long been achieved by addition of short flexible linkers (for example the use of ”GAG” in
place of the variable loops on HIV gp120[116], or the use of ”GGGG” in place of the RRF
globular domain[117, 118] ) those efforts typically require a certain amount of empirical
testing and are not suited to design segments that interact with and stabilize the core of the
protein as we have done here. Our results on resurfacing indicate that it may be possible
to modify all potential antibody epitopes (or other types of binding sites) on the surface
of a protein outside a particular function or binding site, while maintaining the stability,
solubility, and functional activity (binding affinity) of the protein of interest. This resur-
facing technology may have applications to improve solubility and/or alter multimerization
propensity; to simplify the binding profiles of proteins with multiple binding sites/partners
facilitating the study of individual interactions, and to design novel antigens and serological
reagents[109].
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3.7 Supplemental Material
3.7.1 Surface plasmon resonance experimental protocol
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Chapter 4
TRANSPLANTATION OF A COMPLEX BINDING SITE USING
COMPUTATIONAL DESIGN AND IN VITRO EVOLUTION
4.1 Abstract
The transplantation of a complex epitope or binding site from one protein of known struc-
ture to other scaffold proteins serves as a challenging test for flexible backbone protein
design and could be employed to devise novel vaccines or binding reagents. We sought
to graft a complex antibody epitope involving two non-contiguous segments from the HIV
gp120 envelope protein onto a heterologous scaffold protein. Within Rosetta, we developed
a general computational method called Multigraft for transplantation of complex epitopes.
Given an input structure of an antibody-epitope complex, Multigraft searches the PDB for
suitable acceptor scaffolds using geometrical criteria, replaces the backbone of the candi-
date scaffolds with the epitope backbone, and employs iterative loop modeling and design
to build a continuous backbone. Starting from a crystal structure of the b12 antibody
in complex with gp120, a number of scaffolds were designed, produced and their affinity
for b12 assayed by SPR. In that first generation, only one scaffold had a detectable and
specific affinity for b12, but the KD (∼300 µM) was significantly higher than the KD for
gp120 (20 nM). To improve b12 binding, computation-guided evolution was undertaken.
Cycles of conformational sampling and design were performed to diversify the sequence of
the connecting regions between the epitope segments and the acceptor protein. Directed
mutagenesis libraries were derived from the resulting sequences and were screened for b12
binding using yeast surface display. The best clone bound b12 with a KD of 35 nM, compa-
rable to the KD for the b12-gp120 interaction. To our knowledge, this is the first successful
backbone transplantation of a discontinuous binding site to a heterologous protein. Fur-
ther, the approach shows how to leverage aggressive computational design with an efficient
in vitro evolution strategy. Lastly, the optimized scaffold could be useful for HIV vaccine
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research to detect or elicit b12-like antibodies.
4.2 Introduction
Several longstanding challenges have recently been met using rational protein design. Most
notable achievements in protein design have relied on the atomic structure of a pre-existing
backbone observed in nature. For example, the latest advances in rational enzyme design
involved the selection of backbones able to support the geometry of two or three catalytic
side chains [30, 31, 32]. The inclusion of backbone flexibility in design calculations presents
significant challenges [119, 107], but has promise to elevate expectation of the field by
allowing for more accurate protein modeling and by expanding the scope of applications of
protein design.
Random mutagenesis and directed evolution approaches have become common labora-
tory tools to manipulate and optimize protein function. The desired improvements are
typically related to binding affinities, catalytic activity and protein solution properties[120].
Some of the selection platforms have obvious advantages such as the possibility of screening
large libraries without having to purify each individual sequence and allow for a reliable
quantification of the property to be improved[121]. Although not required, a starting se-
quence with some measurable level of the desired property can contribute to the success of
in vitro evolution experiments[30]. Frequently, multiple rounds of mutagenesis and selection
are performed to generate clusters of mutations in a way that most of these mutations will
synergistically improve the property under selection[122]. Computational design has been
helpful in providing starting sequences[30] with large potential for improvement. Several
examples have been described in the literature of computational designs successfully op-
timized using in vitro evolution and also approaches that utilize computationally inspired
libraries[123, 124].
Here we describe our approach to tackle a relevant biomedical problem, the engineering
of ”epitope-scaffolds” onto which the complex HIV b12 broadly neutralizing epitope was
transplanted. Several HIV broadly neutralizing antibodies (bNAb) have been isolated and
they neutralize efficiently most strains of the virus. b12 was the first bNAb isolated from
a human infected patient using phage display techniques[125]. The elicitation of bNAbs is
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likely critical for the efficacy of an HIV vaccine and the retrovaccinology[50] approach has
been focused in trying to elicit known bNAbs, creating the need for structure-based design
approaches. In particular the epitope-scaffolds, molecules that did not evolve to escape the
immune system and lack all the molecular trickery typical of the pathogen’s molecules[126].
A fundamental aspect about the viability of the retrovaccinology strategy is to know if
the bNAbs will efficiently neutralize the virus in humans, optimistic indications came from
studies in animal models where b12 has shown sterile protection in macaques challenged
with and HIV-1/SIV chimeric virus[127, 128]. Vaccines have been successful by using native
molecules of pathogens or variations of live attenuated pathogens[76]. Despite all the efforts
employed in the optimization of gp120 and gp41, molecules that compose the HIV viral
spike, they were never able to elicit useful neutralizing responses, although several bNAbs
that target both molecules are known[129]. The HIV viral spike is composed of trimers of 2
distinct subunits (gp41 and gp120); the binding surface of the broadly neutralizing antibody
b12 with gp120 overlaps with the CD4 binding site on gp120, and the interaction with CD4
is conserved and required for cell-invasion[129]. Hence, the elicitation of antibodies similar
to b12 would likely be relevant for vaccine development purposes.
The b12-gp120 complex has been characterized by x-ray crystallography[74], gp120 has
been co-crystallized with other molecules where the binding surface also overlaps with the
CD4 binding site[130, 131], showing the remarkable conformational plasticity intrinsic to
this site. Additionally, the b12 binding site is a complex epitope where the interactions
with gp120 are comprised within several discontinuous segments of the protein[74]. The
structural knowledge accumulated over the years, enables the use of rational design strategies
to transplant the key structural motif to scaffold proteins where it will be conformationally
stabilized for a robust presentation to the immune system.
The transplantation of the b12 complex epitope poses a challenge to rational design
strategies, serving as proxy to tackle other relevant problems using protein design. Here,
we describe a general strategy to accomplish complex epitope transplantations to unrelated
protein scaffolds (Figure 4.1): (i) a general matching scheme to select host scaffolds for
epitope transplantation (Figure 4.2); (ii) flexible backbone design to connect the epitope
to the scaffold; (iii) a structure-sequence diversification protocol (Figure 4.3) to design
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computationally inspired libraries that are then screened in an in vitro evolution platform.
To our knowledge, this is the first successful backbone transplantation of a discontinuous
binding site onto an heterologous protein.
Figure 4.1: Overview of combined computational and experimental strategy. (I) b12-gp120
complex (PBDid: 2NY7) was used to identify host scaffolds. gp120 is colored in green, the
b12 antibody is colored in magenta and gray, the b12 epitope is colored in yellow. (II) The
matching algorithm searched for scaffolds determined the orientation of the host scaffold
(blue) and the epitope loops (yellow). After a first computational design step that connects
the epitope to the scaffold, computational guided libraries were designed and screened using
yeast surface display. (III) Computational model of the epitope-scaffold.
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Figure 4.3: Step-by-step computational protocol for structure-sequence diversification. (I)
Backbone sampling of epitope connecting segments using loop prediction type techniques[39,
110]. (II) C-alphas of design positions for each of the simulations are represented in spheres.
Blue spheres were designable positions in the simulation for segment 1N, cyan and magenta
positions were designed in the simulation for segment 2N and cyan and green were used
on simulations of segment 2C. (III) In silico recombination of conformations of different
segments was performed to ensure structural compatibility. (IV) After the recombination
and design steps, loop prediction simulations for segment 2N were performed and the loop
sequence showed energetic preference for the initial conformation of the design. Three
directed libraries were designed based on the sequence profiles after filtering the designs
using structural quality indicators like full-atom energy, packing score and buried unsatisfied
polar atoms.
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4.3 Materials and Methods
4.3.1 Computational Matching and Design
Matching
The automated matching (Figure 4.2) and design stages of the grafting protocol were imple-
mented in the Rosetta modeling platform. The matching stage exhaustively searched 13337
single chains from the PDB[4]. Loop 1 of the epitope (364 to 373, 2NY7 numbering) was
defined as primary loop, and it sets the rigid body orientation between the query scaffold
and the antibody. The second loop was considered secondary and honors the orientation
of the initial complex. The computational algorithm takes as input the structure of the
epitope loops in complex with the antibody and a file defining sub-ranges of the epitope.
A C2N superposition scheme was used to search for primary loop matches, the last residue
on the C-terminus of the primary epitope loop was aligned onto every residue of the query
scaffolds and RMSDs were measured between the N-terminus of the loop and each residue
of the query scaffold. If the RMSD between the N-terminus of the epitope and the query
residue was bellow a user defined threshold (2 A˚), a primary match was found. Upon
identification of a primary match, the initial 2 loop epitope was recovered maintaining the
original rigid body orientation, next the algorithm queried the scaffold for matches to the
secondary loop. Secondary matches were searched based on the RMSD between the N and
C termini residues of the second loop and two residues on the query scaffold using also a user
defined RMSD threshold (5 A˚). To finalize, the antibody was aligned to a hybrid-structure
composed by the query scaffold with the epitope in the putative match location, and steric
clashes were measured between the epitope and the scaffold (intra-clash), and between the
scaffold and the antibody (inter-clash). Matches were discarded based on several criteria:
the distance between the junction points of the epitope loop and the scaffold, inter-clash
and intra-clash scores.
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Modeling and design of the junctions between scaffolds and the epitope
The first round of design was performed using the Remodel algorithm (Huang et al. in
preparation) implemented in Rosetta. The alignment between the scaffold and the epitope
loops produced by the matching stage was recreated and three gaps in the polypeptide chain
were closed using loop modeling and design. The starting structure for the remodel stage
was obtain as follows: A) for Loop 1 the segment comprised between the residues 115-130
(PDBid:2bod numbering) was replaced by the segment of gp120 from residue 365 to 372
with residue 372 (Loop 1 gp120) being superimposed to residue 130 (2bod); B) for Loop
2 the original orientation relative to Loop 1 was recovered and residues 73 to 92 from the
scaffold were replaced with residues 472 to 476 from gp120. The remodel algorithm samples
backbone conformations by doing steps of fragment insertion[111] and Cyclic Coordinates
Descendent (CCD)[39, 110] ensuring that the connectivity of the polypeptide chain is main-
tained, followed by a step of RosettaDesign[15] and full-atom minimization. The rebuilding
and design steps were performed in the presence of the b12 antibody. In Remodel simu-
lations a loop of four residues was built connecting residue 114 (PDBid:2bod numbering)
to 365 (gp120 numbering) and 365 was also allowed to move to improve efficiency of the
chain closure algorithm. For Loop 2 connecting regions in the N and C termini, four and
three residue segments were built respectively, and both edge residues of epitope Loop 2
were allowed to move. Other lengths for the connecting segments were attempted and the
reported lengths were selected based on the higher efficiency of the algorithm closing back-
bone gaps. The designs resulting from the remodeling stage were selected based on several
scores: full atom energy, Ramachandran score and counts of polar buried unsatisfied atoms,
as implemented in Rosetta++[111].
Structure-sequence diversification
The algorithm described by wang et al. and Qian et al. [39, 38] was used to generate
structural ensembles of segments upstream and downstream of the epitope residues in the
absence of the b12 antibody. 20,000 models for each individual segment were generated in
the context of the initial design (Figure 4.3). The best 1,000 models by Rosetta energy
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were selected for a following design stage and for each loop relax model 10 designs were
generated; the designed positions are shown in figure 4.3. A first redundancy filter was
applied to the 10000 designs to eliminate models with the same Rosetta full atom energy,
reducing the number of designs by approximately 90%. Next, designs were filtered according
to the Ramachandran score, the criteria used was to discard all the designs with a energy
higher than the initial computational design (12 energy units). The complex between b12
and the remaining designs was recreated, followed by an interface side-chain repacking step
for an accurate calculation of the interaction energy between the two molecules and as a
last step of filtering all the designs with an interaction energy higher than 0 were discarded
(implying that there were steric clashes at the interface). After the filtering stage, 633
designs for loop 2N, 1,202 for loop 2C and 370 for loop 1N remained.
The computational models suggested that the sampled segments would likely interact
with each other. Although simulations of the 3 segments sampled simultaneously were per-
formed, the best scoring solutions did not converge to solutions with well ordered secondary
structure elements, such as the solutions observed with only one of the segments sampled
(particularly for loop 2C). We acknowledged the necessity of combining the best solutions
obtained for individual loops, insuring structural compatibility between them. A small set
of designs selected from the single loop simulations where then explicitly recombined in an
all-against-all fashion. The atomic coordinates from loop 1N variants were explicitly com-
bined with all variants of loop 2N and resulting variants were then combined with loop 2C.
Single segment designs were recombined as follows: 9 designs for loop 1N, 7 for loop 2N
and 4 loop 2C; resulting in a total of 252 different combinations. The designs were selected
based on Rosetta full-atom energy and a double filtering criteria where the designs on the
top 20% by energy were then selected according to a packing score[112] and counts of polar
buried unsatisfied atoms. After the explicit recombination of the segments one more step
of design was performed in positions allowed to change in all single segment simulations.
Next, 6 different designs were selected for the last step of flexible backbone sampling and
design. The designed variants were selected by Rosetta energy, but also according to the
diversity of the backbones. The final 6 designs incorporated 1 variant of loop 2C, 2 variants
of loop 2N and 3 variants of loop 1N. According to the single segment simulations, loop 2N
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potentially interacted with both other segments. Hence loop 2N was the most adequate loop
to perform a final round of conformational sampling, insuring that the three segments were
optimized in the presence of each other. A last step of design and filtering was performed
according to the same protocol described for the single segment ensemble generation.
Library design
A small subset of designs was selected to assemble a directed library. The designs generated
from the last 6 ensembles were further filtered, using a triple criteria were the designs had
to be part of the top 5% by full atom energy, packing and counts of buried unsatisfied.
To further reduce the number of designs after the first filter, only the top scoring designs
were considered and designs with obvious flaws such as buried polar side chain atoms were
discarded after visual inspection. We also considered the initial models obtained after the
recombination and design step. The frequencies of amino acids for each designable position
were computed and Rosetta models where different amino acids occurred were visually
evaluated. To reduce the size of the library, some amino acids that occurred on Rosetta
models were discarded upon visual inspection typically for one of two reasons: A) buried
side chain polar atoms; B) under-packed structure. The observed frequencies in Rosetta
models and amino acids included in the libraries are shown in Figure 4.11.
4.3.2 In vitro evolution and Selection
The genes encoding 2bodx 003 and 2bodx 004 designs were synthesized with optimized
codon usage and subcloned into pET29b vector (Codon Devices, Genscript Corp.). For
library construction, these genes were extracted and extended by PCR to add regions of
homology to the pCTCONC2 vector. The random mutagenesis library was generated with
the Gene Morph II Random Mutagenesis kit (Strategene) under reaction conditions that
resulted in ∼4 mutations per gene. For the directed libraries, multiple oligos were used to
span the desired sequence diversity for Loop 1 or Loop 2 while avoiding the addition of
stop codons and limiting the number of undesired gene variants due to degenerate codons.
Loop 1 or Loop 2 ultramer oligos (IDT) were transformed into double stranded DNA and
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combined with two non-mutated DNA fragments extracted from the original 2bodx 004 gene
(Figure 4.12) to form full-length gene variants during homologous recombination in yeast.
Libraries were transformed and screened using a yeast surface display system previously
described [132, 121]. Briefly, S. Cerevisiae EBY100 competent cells were transformed with
1µg of pCTCONC2 triple-cut vector (BamHI/SalI/NheI, NEB)and a 20x molar excess of
library DNA using electroporation. Typical transformation efficiency ranged from 106 to
107 for a 1x transformation and more than 90% of the recovered sequences from the nave
libraries contained full-length in-frame gene variants. The resulting yeast culture was grown
at 30 oC, 250 rpm in 2% glucose C-trp-ura media and passaged at least ttwice. Once the
culture reached a density of 2x107-3x107 cells/mL it was transferred to 2% galactose C-
trp-ura media and grown for 14-16 hours to induce protein expression on the surface of
yeast. 106 to 108 yeast cells were then pelleted and washed three times with PBSA buffer
(0.01 M sodium phosphate, pH 7.4, 0.137 M sodium chloride, 1 g/L bovine serum albumin).
Cells were then incubated with MAb b12 IgG on an orbital shaker for 1 hour at 4 oC.
Finally, cells were pelletted, washed three times and fluorescently labeled with phycoerythrin
conjugated a-hIgG (Invotrogen) and fluorescein isothiocyanate labeled a-cMyc Ab at 4 oC
for 1 hour. Cells were analyzed using fluorescence activated cell sorting (BD Influx, BD
Biosciences) and double positive clones were sorted, expanded, induced and labeled as
before for additional rounds of screening. Decreasing MAb b12 IgG concentrations were
used for labeling subsequent selection rounds to reduce library diversity and select high
affinity clones. Individual clones were selected after each round and their DNA was isolated
using the Zymoprep II kit (Zymo Research). Standard PCR was used to amplify the gene
of interest from this DNA and the resulting product was sent for sequence analysis.
4.3.3 Protein Expression and Purification
DNA segments encoding scaffold constructs were synthesized with optimized codon usage
and RNA structure (Codon Devices, Genscript Corp.), subcloned into pET29 (EMD Bio-
sciences) and transformed into Arctic ExpressTME. coli (Invitrogen). Single colonies from
the transformation were grown overnight at 37 oC in starter cultures with Luria Broth (LB)
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plus Kanamycin (100 mg/ml). 10 mL of starter cultures were expanded into 1 L of LB
plus Kanamycin (100 mg/mL) and incubated at 37 oC, 250 µM of IPTG were added to the
culture when log phase was reached and incubated overnight to induce protein expression
at 12 oC. Cultures were then pelleted and resuspended in start buffer (160 mM Imidazole,
4 M Sodium Chloride, 160 mM Sodium Phosphate), a tablet of protease inhibitor (Roche)
was added and the cell suspension was frozen at -20 oC. The cell suspension was thawed
and 10ml of 10x Bugbuster (Novagen), 50 µL of Benzonase Nucleases (Novagen) and 1.7
µL of rLysozyme (Novagen) were added to lyse the cells, the suspension was then gently
tumbled in an orbital shaker for 20 minutes. Lysed cells were pelleted and the supernatant
was filtered through a 0.2 micron filter (Millipore). Supernatants were tumbled with 5 mL
of nickel-NTA resin (Fisher) for 1 hour at 4 oC. The resin was washed then rinsed with
Wash Buffer (50 mM imidazole, 500 mM Sodium Chloride and 160 mM Sodium Phosphate)
and eluted with elution buffer(250 mM Imidazole, 500 mM Sodium Chloride and 20 mM
Sodium Phosphate). Fractions containing the construct of interest were combined and fur-
ther purified by preparative size exclusion chromatography (SEC) on Superdex 75 16/60
(GE Healthcare) at room temperature in PBS or HBS. Fractions containing the protein
of interest were collected, confirmed by SDS page and concentrated by ultrafiltration (Vi-
vaspin, Bioexpress). Protein concentration was determined by measuring UV absorption
signal at 280 nm and calculated from known amino acid composition extinction coefficient.
Site-directed mutagenesis was performed following the ”Kunkel” method[133, 134].
4.3.4 Solution Oligomerization State and Circular Dichroism
The monodispersivity and molecular weight were further assess by analytical SEC (Agilent,
1200 series) coupled to an on-line static light scatter (SLS)(miniDAWN TREOS, Wyatt).
The molecular weight determination was performed with the ASTRA software (Wyatt).
Solution thermostabilities (Tm) were determined by circular dichroism with an Aviv 62A
DS spectrometer. Far-UV wavelength scans (260 nm - 190 nm) at approximately 20 µM
protein concentration were collected in a 1 mm path length cuvette. Temperature-induced
protein denaturation was followed by change in ellipticity at 220 nm.
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4.3.5 Biacore
All experiments were carried out on BIACORE 2000 at 25 oC. Running buffer HBSEP
(0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA and 0.005% (v/v) Surfactant P20) (GE
Healthcare). For analysis the human antibodies were captured on Research grade CM5
sensor chip containing 8000-9000 RUs of Anti-Human IgG from Human Antibody Capture
kit (GE Healthcare). The Anti-Human IgG was immobilized in all four flow cells including
a reference flow cell at similar levels using Amine Coupling kit (GE Healthcare) according
to the manufacturers manual. All data were collected using two replicate injections for each
concentration of analyte. The regeneration was performed when needed with 60 seconds
injection of 3 M MgCl2 from Human Antibody Capture kit. Flow rates during the exper-
iment were maintained at 50-100 µl/min. Data preparation and analysis were performed
using Scrubber software (version 2.0, BioLogic Software,Campbell, Australia). For kinetic
analysis biosensor data were globally fit to a mass transport limited simple bimolecular
binding model:
A0 represents injected analyte
For equilibrium analysis each data set was fitted to a single site interaction model:
Req - response value at equilibrium
CA - concentration of the analyte
Rmax - maximum response when all binding sites are occupied by the analyte
KD - dissociation constant
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4.4 Results
4.4.1 Computational Design
The Protein Data Bank was searched for acceptor scaffolds able to accommodate the b12-
bound conformation of the two main epitope-loops from gp120. A detailed description
of the matching algorithm is given in the methods section and also outlined in Figure 2.
The matching strategy used to select the discussed scaffold (2bodx) was C2N match in the
primary loop (Loop 1) and end point match for the secondary loop (Loop 2). In a C2N
match the residue on the C terminus of the loop is superimposed on each residue of the
query scaffold, and RMSDs of the N terminus residue were measured to all the residues of
the query protein. Alignments where the RMSD was lower than a user-defined threshold (2
A˚) were kept, resulting in a primary match. Next, Loop 2 was aligned in all the primary
matches to recreate the orientation of the b12-gp120 complex. RMSDs were measured
between both ends of Loop 2 and residues in the query scaffold, and if the values were
bellow a user-defined threshold (5 A˚) the alignment of the two loops on the scaffold was
accepted as a match. Matches were then filtered by backbone clashes between epitope and
scaffold (defined as intra-clash), and backbone clashes between the scaffold and the antibody
(defined as inter-clash). Several variants of the matching schemes were attempted: Loop 1
superposition with Loop 2 end point match; Loop 2 superposition with Loop 1 end point
match. Multiple variants based on 11 different scaffolds were experimentally characterized.
Most of the proteins were barely soluble or insoluble with the exception of the ones based
on 2 different scaffolds one of them the 2bodx scaffold.
The choice to focus in 2bodx scaffold was made primarily for three reasons: the matching
scheme allowed to take advantage of the only ordered secondary structure element in the
target epitope a helical turn in the basis of Loop 1 (C terminus), which served as an ”anchor”
for the placement of the epitope on a helix terminus; upon a search for homologues of 2bodx
the region remodeled showed high structural plasticity (Figure 4.9), strongly suggesting that
the scaffold region could tolerate multiple sequence/structure solutions; the experimental
feedback from the first round, where most of the 2bodx designs were expressed in E. coli
and soluble to high concentrations, and one of the designs also bound weakly to b12 but
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specifically by SPR (Figure 4.10).
From the first round of pure computational design, 8 constructs were expressed in E.
coli, 6 were soluble and purifiable using immobilized metal affinity chromatography and
SEC. The solution oligomerization state was analyzed by Static Light Scattering (SLS) and
SEC and the designs were monodisperse and monomeric in solution. SPR was performed
to assess binding to antibody, 2 of the designs showed signal above background (2bodx 003
and 2bodx 004), with 003 showing a higher response than 004. The difference between
the two constructs was that 003 had a disulfide bond further in space and in sequence
from the modeled region, but that could potentially impact b12 binding according to the
computational model. The extremely low affinity assessed by SPR made the specificity of
the scaffold-b12 interaction questionable. To clearly address the binding specificity issue, a
knockout variant (D140R) of the 003 design was tested by SPR, and binding was abolished
by this single point mutation that has been reported to have the same effect in the b12-gp120
interaction[135].
The results for the initial computational design showed two desirable features for the
following optimization stage: the scaffold tolerated a large number of mutations including
deletions and insertions, while remaining a soluble and well behaved molecule; and specific
binding to the b12 antibody, with approximately 10,000 fold lower affinity than that of
gp120.
4.4.2 Computationally Inspired Libraries and In Vitro Evolution
Following the results from the computational design round, we undertook a mixed computa-
tional and in vitro evolution approach to generate and screen multiple variants of 2bodx 003
epitope-scaffold. We hypothesized that optimizing the connecting regions between the epi-
tope loops and the scaffold would lead to better epitope stabilization, resulting in higher
affinity for b12 MAb. Given the large number of residues involved in epitope stabilization
(16) (Figure 4.3) as well as the possible interactions between the two loops, an effective way
to investigate this large sequence/structure space was to first computationally determine
energetically favorable sequences for Loop 1 and Loop 2 connecting segments. From the
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best models, the resulting amino acid diversities at each of the 16 critical positions were
merged and analyzed as two directed libraries displayed on the surface of yeast.
The computational protocol of sequence-structure diversification was devised on a phi-
losophy of ”divide and conquer”. First, the connecting segments of Loop 1 N-terminus,
Loop 2 C-terminus and Loop 2 N-terminus were individually modeled to ensure fine sam-
pling of the structural segments (Figure 4.3). The sequence-structure diversification was
achieved using Rosetta loop prediction[39] for the generation of structural ensembles and
RosettaDesign[15] for sequence diversification. The resulting models were evaluated based
on several of the implemented Rosetta energies, such as the Ramachandran distribution of
the backbone dihedral angles[111], packing[112] and buried unsatisfied polar atoms counts.
In a second step, the best solutions for the individual segments were combined iteratively
and additional computational modeling ensured their structural compatibility (Figure 4.3).
The resulting models have better Rosetta metrics than the original 2bodx 003 design,
suggesting that more energetically favorable regions of the sequence/structure landscape
were indeed sampled. This iterative procedure might thus serve as an efficient way to avoid
entrapment in local energy minima, similarly to previously described strategies[48].The
best 45 models were aligned and showed sequence diversity at positions 72-76, 80-83, 86
and 107-110, 121, 125 for Loop 2 and Loop 1 connecting regions respectively (Figure 4.4).
Residue frequencies at these positions (Figure 4.11) showed good sequence convergence in
some cases (76, 86, 110), but most often no consensus residue was identified. Furthermore,
at some positions (72,107,109) there was no preference for a given type of amino acid (i.e.
polar, hydrophobic), underscoring the vast structure and sequence space explored during
the modeling as well as the large number of conformations of the loop connecting regions.
To investigate the diversity present in the best 45 models, two directed libraries were
built and screened for b12 MAb binding by florescent activated cell sorting on the surface
of yeast[132, 121]. Although it would have been ideal to investigate both Loop 1 and Loop
2 diversity simultaneously, the large number of possible combinations (1012) compared to
the regular size of yeast libraries (107) made this impractical. To further reduce the library
size, the best 45 models were visually inspected and some residue identities were excluded
based on their low frequency or other undesired characteristics such as buried side chain
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polar atoms.
Figure 4.4: Residues sampled in computational design calculations to inspire directed li-
braries. The C-alpha atoms are shown in spheres being labeled with the residue number.
The first library (Library 1) (Figure 4.11) covered the sequence diversity of Loop 2
(4x106) combined with 8 variants of Loop 1 present in 23 out of the 45 models that were
used to generate the library. Including multiple Loop 1 variants was deemed important
to avoid any potential incompatibility between Loop 1 and Loop 2 sequences. The second
library (Library 2) (Figure 4.11), covered the sequence diversity of Loop 1 (2x105) combined
with the best Loop 2 variants identified from Library 1. Additional diversity was added
to the libraries due to codon degeneracy, and some of the previously modified residues in
2bodx 003 were allowed to revert to their native identity since they were considered non-
essential for epitope stability. Overall, 21 positions were allowed to change with different
degrees of variability in the two libraries.
Before screening Libraries 1 and 2 , a random mutagenesis library was constructed to
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optimize the yeast surface display levels of 2bodx 003. This resulted in the isolation of
clone 2bodx Y3 which was different by two mutations, A118V and S177G, compared to
the computational design. S177G removed a putative glycosilation site which might have
interfered with protein folding in yeast, while A118V added a contact present in the gp120-
b12 complex to 2bodx 003. 2bodx Y3 not only had increased cell surface display levels,
but also showed higher affinity for b12 (Table 4.1, Figure 4.6). The S177G mutation was
included in Libraries 1 and 2, but A118V was not added at this stage since the computational
modeling did not allowed any variability at that position.
The Libraries were generated and transformed by taking advantage of yeast homologous
recombination. Specifically, Loop 1 and Loop 2 encoding DNA fragments were mixed with
non-variable regions of the 2bodx 003 gene to form full length genes when transformed with
pCTCONC2 vector (Figure 4.12). This approach facilitates library construction and adds
an additional diversification step due to DNA shuffling[121].
Library 1 was screened with decreasing b12 IgG concentrations (1 µM, 1 µM, 100 nM, 10
nM, 1 nM) for 5 rounds (Figure 4.5 and Figure 4.13). Increased b12 binding was observed
during the selections, and after the fourth round the library complexity was reduced to 3
different clones. An additional round of selection resulted in convergence to clone 2bodx 032.
To construct Library 2, we decided to combine all the variants present after the third
selection round of the Library 1 with the computationally determined diversity of Loop 1
(Figure 4.11). The DNA of 48 individual clones from the third selection round of Library 1
was sequenced and 18 different sequences were identified, with 12 of them represented more
than once. We choose to include several Loop 2 variants for Library 2, rather than just
the single converged clone (2bodx 032), to account for the possibility that in the presence
of different Loop 1s other Loop 2s might be better for b12 binding due to their structural
proximity. Indeed, after 3 rounds of selection at 10 nM, 100 pM and 10 pM b12 IgG
respectively, Library 2 converged to a single clone, 2bodx 042, which had a sequence for
Loop 2 different from 2bodx 032. This Loop 2 sequence was present in only 2% of the
clones from the third selection round of Library 1. A third library (Library 3) was devised
to optimize buried or partially buried residues underneath the epitope loops that were
under-sampled in Libraries 1 and 2.
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Screening Library 1 with b12 IgG was advantageous because it allowed identification
of low affinity binders due to avidity effects. However, Library 2 showed increased surface
display levels compared to Library 1 (data not shown), raising the possibility that clones
were being selected for increased avidity instead of affinity. To eliminate this possibility,
Library 2 was re-screened with biotin-b12 Fab (data not shown) and it converged to the
same 2bodx 042 clone as when screened with b12 IgG.
Figure 4.5: Sequential screening of directed libraries to obtain an improved b12 binder. A
library targeting Loop 2 (Library 1) connecting segments was screened in the presence of
8 variants of Loop 1. Sequence convergence for Library 1 was reached after 5 rounds of
selection, resulting in 3 different clones. A library targeting Loop 1 (Library 2) connecting
segments was screened in the presence of 18 Loop 2 variants selected from the 3rd selection
round of the Library 1.
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4.4.3 Affinity and Specificity
The 2bodx variants identified from the selections experiments were expressed recombinantly
in E. coli and biophysically characterized. Dissociation constants (KDs) for the b12 inter-
action of multiple clones were determined by SPR (Table 4.1, Figure 4.6).
2bodx Y3 had a KD for b12 of 30 µM, a 10 fold improvement over 2bodx 003, most
likely due to additional contacts made by V118 with the Ab. This residue is also present
at the corresponding position on gp120 and interacts with b12 in the crystal structure of
the complex. However, V118 cannot be modeled on 2bodx 003 without introducing a steric
clash between the epitope-scaffold and the CDRH3 of b12. This suggests inaccuracies either
in the scaffold-antibody rigid body orientation or unaccounted flexibility from the CDRH3 of
b12 which may alleviate the clash. 2bodx 032 had the same Loop 1 sequence as 2bodx 003,
but differed by 8 mutations in loop 2, which resulted in a b12 affinity of 13 µM. The highest
affinity clone isolated from Library 2 (2bodx 042) bound b12 with a KD of 166 nM. This
variant had 17 mutations relative to 2bodx 003 distributed over both the Loop 1 and Loop
2 connecting regions. Introducing the A118V mutation on 2bodx 042 resulted in a new
variant (2bodx 043) which bound b12 with a 33 nM affinity. Two additional mutations
(P83 and M124) selected in Library 3 improved b12 affinity to 10 nM. Sequence changes for
all the mentioned clones can be found in Table 4.2.
Table 4.1: Kinetics and equilibrium b12 binding constants for selected clones were assessed
by SPR. b12 binding affinity of the 2bodx 43 clone is in the same range as the b12-gp120
interaction.
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Figure 4.6: Equilibrium curves and sensorgrams assessed by SPR. b12 binding affinity of the
2bodx 43 and 45 clones are in the same range as the b12-gp120 interaction. (A) Equilibrium
binding curves determined by SPR. (B) SPR kinetic analysis of 2bodx 43 interacting with
b12 IgG. The kinetic fits are shown in red.
The affinity range of the best clones is similar to the KD of b12 for gp120 (20 nM [74])
and 30,000 times better than the original computational design. To probe the specificity of
2bodx 043, residue D104 was changed to R, which resulted in complete loss of binding to
b12 (Figure 4.8), similar to the effect of the D368R mutation on gp120. Circular Dichroism
experiments showed that the protein was stable (Tm ∼ 75 oC) and well folded (Figure 4.7A
and B). Static light scattering analysis revealed that 2bodx 043 was monomeric (Figure
4.7C).
The CD4 binding site (CD4bs) in gp120 is a known site of interaction for multiple
antibodies against HIV-1. To evaluate the specificity of the transplanted binding site in the
context of the scaffold,the binding of 2bodx 043 to CD4 and a panel of 9 CD4bs antibodies
was assessed by SPR. 2bodx 43 was highly specific for b12 MAb and did not interact with
any other CD4bs Abs or with CD4 itself even at high concentrations (Figure 4.8). Based
on the structural information available for the antibodies tested, the lack of binding is due
to either insufficient contacts made with 2bodx 043 (CD4, VRC01, etc.), to the different
conformations these Abs induce in Loop 1 and 2 upon binding, or to steric barriers present
on the scaffold but absent from gp120. The b12 specificity shows that through our combined
in silico/in vitro approach we successfully transplanted a complex binding site known for its
promiscuity, and stabilized it in the precise conformation to recognize only its target ligand
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Table 4.2: Sequence changes of the selected clones relative to the initial computational
design. Residue numbers are indicated on the top of each sequence column. The epitope
residues are colored in red.
CD - Computational Design
RL - Randoom Library
L1- Library 1
L2 - Library 2
L3 - Library 3
with high affinity.
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Figure 4.7: Thermal stability and solution oligomerization state. 2bodx 43 is folded and
monomeric. Circular Dichroism shows a characteristic spectrum of a folded α/β protein.
Thermal denaturation shows cooperative unfolding with a Tm of ∼75 oC. Size exclusion
cromatography (SEC) and static light scattering (SLS) show a monomer in solution with
the expected molecular weight of ∼30 kDa.
Figure 4.8: 2bodx 43 shows highly specific binding to b12. (A) Knockout mutation from
the b12-gp120 interaction shows the same effect in 2bodx 43. (B) Multiple antibodies that
bind to the CD4 binding site of gp120, 2bodx 43 only binds to b12.
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4.5 Discussion
To our knowledge, we accomplished the first complex epitope transplantation to a heterol-
ogous protein using computational methods together with in vitro evolution. The aggres-
siveness inherent to this design problem is considerable, where the scaffold was ”sculpted”
to accommodate a complex epitope, including changes on the length of several segments
as well as drastic alterations in their secondary structure. The devised strategy enabled
the design of a starting sequence with weak binding activity (KD ∼300 µM ) that was fur-
ther optimized using in vitro evolution leveraged by computationally inspired libraries to
achieve an improvement in affinity on the order of 30,000 fold. The best epitope-scaffolds
bind b12 with dissociation constants in the same range of the original b12-gp120 interaction
(20 nM). The epitope-scaffold is highly specific, engaging the predefined target antibody but
not other ligands known to engage the same site on gp120, further validating the rational
strategy taken.
The computational methodologies presented are applicable to a wide range of challenges
dealing with backbone grafting, spanning the single segment to multiple segments grafting
(2 or more). The matching scheme is able to perform multiple types of alignments, al-
lowing the selection of the most appropriate scaffolds according to intrinsic features of the
target binding site. Given the aggressive remodeling required, a flexible backbone design
approach was devised to optimize individual remodeled segments that were then recombined
to generate a directed library. The library was efficiently and rapidly screened in a yeast
display format. Given the observed improvements, it is appealing to argue that routine
use of flexibility in protein design will enable greater steps in the improvement of desired
functions.
The results described open several novel routes to the field of vaccine design, where
strategies to generate candidate molecules have been limited to variations based on the
pathogen’s native molecules, or scaffolding of linear epitopes by side chain grafting (Chap-
ter 2). The specificity shown by the scaffold is a key feature for promising immunogens,
since the main aim is to re-elicit a particular kind of neutralizing antibodies and dampen the
elicitation of all the non-neutralizing ones. The possible applications are not limited to vac-
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cine design but also for other applications that require extremely aggressive computational
design such as enzyme design or protein interaction inhibitors.
In order to benchmark properly the computational design protocol, crystal structures
are being solved. Similarly to evaluate the immunogenic profile of the designs, immunization
experiments are ongoing.
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Figure 4.9: Structural diversity of 2bodx homologues. Corresponding regions to the re-
modeled segments of 2bodx homologous show an appreciable structural diversity. 2bodx
is colored in cyan and the remodeled regions were colored in yellow. For clarity only the
corresponding segments to the 2bodx remodeled regions of one homologue (PDBid: 1gz1)
are shown in red. The observed diversity suggested that these particular segments could be
designed without impacting the overall structural stability.
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Figure 4.10: B12 binding of a knockout mutant of the initial computational design. (A)
SPR sensorgrams where 2bodx 003 (solid lines) shows higher responses at equivalent con-
centrations comparing to its knockout version (dashed lines). (B) The knockout mutation
in gp120 that depletes b12 binding is D368R. A model of the equivalent mutation in 2bodx
is shown.
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Figure 4.11: Amino acid frequencies in residues designed with Rosetta. After a selection of
the designed models according to structural quality indicators, amino acid frequencies were
computed for each residue. Filled bars indicate the amino acids included in the directed
library. (A) Positions considered for Loop 2 region. (B) Positions considered for Loop 1
region.
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Figure 4.12: Homologous recombination strategy to screen sequentially directed libraries.
The 2bodx gene was split into four segments by PCR, 2 of them had no positions targeted
by the library and another two that encoded Loop 1 and Loop 2 of the b12 epitope. Initially
the full Library 1 (Loop 2) was screened in the presence of eight variants of Loop 1 and the
Library 2 (Loop 1) was transformed together with sequences of an early round of selection
with at least 18 different sequences for the Loop 2 region.
Figure 4.13: Facsograms of the 1st and 3rd rounds of sorting for Libraries 1 and 2. The
sorts of Library 1 were performed with 1 µM and 100 nM b12 for the 1st and 3rd round
respectively. For Library 2 the concentrations used were 10 nM and 10 pM in the 1st and
3rd sort.
115
Chapter 5
FOLD FROM LOOPS - FOLDING PROTEINS TO STABILIZE
FUNCTIONAL SITES
5.1 Abstract
Many advances in computational protein design have been accomplished in the past few
years. Despite all the progress, encoding function into computationally designed proteins
remains a difficult task. Typically, to engineer function into proteins a small number of
residues, predicted to confer the desired functionality, are designed on a naturally occurring
protein scaffold able to accommodate these mutations. Functions such as the design of
catalytic activity, creation of a binding sites and specific small ligand receptors have been
successfully engineered. These methods to engineer function usually treat the scaffold as a
rigid body, allowing little or no backbone flexibility. While this strategy has been successful,
there are several bottlenecks for the routine design of function into proteins. The potential
scaffold space is limited to folds observed in nature for which a high-resolution crystal struc-
ture has been solved. Additionally, the lack of backbone flexibility in the current approaches
further limits the usage of the available scaffolds and hinders the ability to identify potential
neighboring residues that can help coordinate the functional side chains. Here we describe a
novel computational protocol called Fold from Loops (FFL) that functions quite differently
to other current strategies. Rather than starting with a protein of known structure and
mutating a small set of side chains to achieve functionality, FFL starts with a structural
motif such as a binding site that already has functionality, and builds a protein around it.
The structural motif is treated as a folding nucleus being held fixed and the target topology
is folded around the structural motif, loosely guided by C-alpha constraints providing max-
imal support and stabilization to the folding nucleus. This protocol was used to stabilize
an epitope of the Respiratory Syncytial Virus (RSV) recognized by the broadly neutralizing
(bn) antibody (Ab) Motavizumab. Several of the designed proteins expressed, were soluble,
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thermally stable and some showed pM affinities to the Motavizumab Ab, in the same range
of affinities measured between the RSV F protein and the bNAb. The results suggest that
the epitope was transplanted with high accuracy and the desired molecular mimicry was
achieved. The computational protocol is general and readily applicable to other design prob-
lems, and we hypothesize that the degree of flexibility allowed in this protocol contributed
critically for the high affinity. It will be challenging to apply FFL to design problems with
discontinuous structural motifs and to fold topologies not yet observed in nature imposing
functional constraints.
5.2 Introduction
The ability to rationally design proteins tailored to perform biological functions a la carte
is a long-standing challenge of computational protein design methods. Notable milestones
have been achieved in the recent past, as the design of enzymes for reactions that lack
natural catalysts[31, 30, 32], modulation of the activity of transcriptions factors[136], newly
reengineered specificities of endonucleases[28] and several successes on manipulating bind-
ing affinities and specificities[26, 24, 102, 103]. Many of the protein interactions observed
in nature have poor binding affinities due to the need of transient and promiscuous inter-
actions in complex biological systems[137, 138]. Nevertheless, the design of high affinity
interactions achieved either by de novo interfaces or by ”polishing” structurally character-
ized interaction motifs has many potential applications ranging from the basic dissection of
cellular pathways to biomedical applications, such as the design of small protein inhibitors
or carrier scaffolds transiently exposed epitopes in viral proteins. Thus far computational
design has been mostly restricted to the ”inverse folding” approach[2, 5] where the design
objects have limited or no flexibility at all. Nevertheless, a basal level of flexibility is al-
ways present in proteins and there has been active development in conformational sampling
techniques for design and prediction. The major hurdle in flexible backbone design is to
sample realistic conformations. Remarkable successes have been reported such as the design
of a new fold[21], the design of loop with sub-angstrom accuracy[48] and specificity switch
using flexible loop backbone[49]. The first two examples aim for a purely structural vali-
dation with no functional constraints, the last example has a functional purpose but most
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of the protein that supports the functional loop is structurally rigid. As eloquently stated
by Havranek et al.[139], design of functional protein requires satisfaction of functional con-
straints and simultaneous energetic optimization, we perceived the need for an approach
orthogonal and complementary to previous reports. Our strategy to satisfy both functional
and energetic constraints was to select a functional site of interest that in silico acts as
the folding nucleus and to fold a target topology around the functional site, in such a way
that the atomistic detail of the folding nucleus is maximally supported by the surrounding
polypeptide chain (Figure 5.1).
Figure 5.1: Overview of the computational procedure - Fold From Loops. The procedure
takes a functional site (such as the helical hairpin represented in cyan) that will be used
as the folding nucleus and remain fixed throughout the procedure. A topology has to be
supplied (magenta) and distance constraints are derived from the input structure to guide
the folding trajectory. The segment in red highlights the location of the folding nucleus.
The polypeptide chain is extended (blue) from the folding nucleus and the chain in then
folded. If the models produced are less than 5 A˚ away from the starting topology they are
discarded, if not are taken through cycles of design and full-atom optimization.
The procedure takes a functional site (such as the helical hairpin represented in cyan
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- Figure 5.1) that will be used as the folding nucleus and remain fixed throughout the
procedure. A topology has to be supplied (magenta - Figure 5.1) and distance constraints
are derived from the input structure to guide the folding trajectory. The segment in red
highlights the location of the folding nucleus. The polypeptide chain is extended (blue -
Figure 5.1) from the folding nucleus and the chain in then folded. If the models produced
are more than 5 A˚ away from the starting topology, they are discarded. Otherwise, they
enter cycles of design and full-atom optimization.
The selected functional site was a conserved epitope on the Fusion Glycoprotein (F pro-
tein) from the Respiratory Syncytial Virus (RSV). RSV is a serious public health problem,
particularly to infants and children, causing 160,000 deaths per year worldwide[140]. The
only available treatment is through passive immunization using the humanized monoclonal
antibody Palivizumab[141]. Due to the potency and breadth of neutralization, this epitope
is an important vaccine target. The epitope is the binding site through which the bn Ab
Palivizumab and an affinity-matured version of Palivizumab, Motavizumab, neutralize the
virus. There is no co-crystal structure of Palivizumab Ab with its epitope, but the pep-
tide epitope is shown to be a helical hairpin when co-crystallized with the Motavizumab
Ab (Figure 5.2). Furthermore, while there is no crystal structure of the F protein, there
are some indications that the epitope might be only transiently exposed[140], making the F
protein an undesirable immunogen. We sought to transplant and stabilize the Motavizumab
epitope as found in the crystal structure with Motavizumab for use as an immunogen to
re-elicit Motavizumab-like antibodies.
The target topology selected was a three-helix bundle, topologically compatible with the
structure of the functional site, which is a helical hairpin[140] (Figure 5.2), nevertheless the
structure of native helical hairpin in the bundle has a different residue length and a struc-
tural alignment reveals an RMSD of 2.6 A˚ between the backbone of the helical segments
(Figure 5.2). Helical bundles have been extensively designed[142, 143, 144], several rational
strategies and multiple functional groups have been incorporated in the helical bundles[145].
Several groups used existing coiled coil structures as static structural templates and imposed
a known sequence pattern observed in coiled coils, the heptad repeat[146]. This new com-
putational method used to stabilize the RSV epitope allows sampling of greater backbone
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flexibility and sequence diversity, while still constraining the structure to accommodate the
functional motif.
Figure 5.2: Motavizumab in complex with peptide-epitope from F-protein of RSV. (A)
Side-view of the complex motavizumab (colored green and magenta) with epitope cyan.
(B) Back-view of the complex. (C) Side chains on the interface of the complex are shown
in sticks.
Here, we describe a general and flexible computational approach to incorporate func-
tional motifs into computationally designed proteins. Our strategy is readily applicable to
wide variety of design problems without major limitations on the use of template topologies
or different binding sites as long as there is a minimal degree (low resolution) of compati-
bility between them. We sought to fold a three-helical bundle of 120 residues around of a
neutralizing epitope of RSV. The computational designs were characterized by a variety of
biophysical methods and were shown to be folded and some with extremely high thermal
stability. More importantly, the designs showed much higher affinities to the motavizumab
Fab than the peptide[140], in the same range as the viral F protein[141]. The computational
strategy together with the experimental validation implies that this bottom-up approach of
folding a protein to ensure structural mimicry and support of a particular functional site
might indeed be a useful and efficient.
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Figure 5.3: Structural differences between the epitope and the topology used as template
to be folded. Target topology is shown in magenta, in red is the location where the epitope
will be placed and in cyan is shown the epitope. The two structures are not superimposable
due to different helix-helix spacing and orientation.
5.3 Material and Methods
5.3.1 Computational Procedure
We developed a general computational procedure as an extension to the Rosetta molecular
modeling package[111, 77]. First, a binding site (PDBid: 3IXT, chain P)[140] and a target
tridimensional topology (PDBid: 3LHP, chain S) are selected. The residue range of the
target topology to be replaced by the binding site is defined. Second, the full atom coordi-
nates of the binding site and the target topology are input and C-alpha distance constraints
extracted from the target topology. Distances between the C-alpha atoms of residues with
a sequence separation larger than 6 are collected outside the range where the binding site
will be inserted. Third, an extended polypeptide chain is grown from the termini of the
binding site atomic coordinates. Resulting in a centroid structure with the original dihedral
angles of the target binding site and all remaining residues are in an extended conforma-
tion. Fourth, the extend chain is folded while the binding site dihedral angles are kept fixed
acting as a folding nucleus. The folding stage is carried using structure prediction type
techniques[147, 22, 148], where C-alpha distances collected from the target topology are
used to restrict the conformational sampling. C-alpha distances of the target topology were
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smoothed by allowing a 1.5 or 3 A˚ of standard deviation. Only structures with a backbone
RMSD less than 5 A˚ relative to the target topology were selected for the full atom stage.
Fifth, original side chain conformations of the binding site are recovered; typically 3 cycles
of iterative design and full-atom optimization are performed. Sixth, an energy filter was
employed and the best 50 designs were selected out of 10,000 for human inspection. Sev-
enth, designs were further filtered according to several structural features Ramachandran
score[111], Packing score[112] and buried unsatisfied atom counts. Additionally, a set of
designs was also selected according to the average helical bend angle of the three helices
as implemented in Helanal[149]. Eighth, surface residues of the initial topology were de-
signed in each of the selected scaffolds, some mutations in the proteins cores were performed
based on human inspection and to mutate overrepresented ALA to VAL/LEU or MET, and
also to get rid of sporadic polar amino acids in the core, followed by a step of full-atom
optimization[111]. The final filtering step was performed based on energy, packing, absence
of steric clashes with the antibody and visual inspection.
Figure 5.4: Structural features of a final FFL design. (A) Structural superposition of the
epitope (colored in red) and the final FFL design (colored in blue). (B) FFL design (colored
in blue with the epitope in cyan) in complex with Motavizumab (show in grey surface).
The computational models of the FFL designs exhibit the adequate compatibility with
the antibody, with no steric clashes or considerable extra contacts between scaffold and
antibody.
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5.3.2 Protein Expression and Purification
DNA segments encoding scaffold constructs were synthesized with optimized codon usage
and RNA structure (Codon Devices, Genscript Corp.), subcloned into pET29 (EMD Bio-
sciences) and transformed into Arctic ExpressTME. coli (Invitrogen). Single colonies from
the transformation were grown overnight at 37 oC in starter cultures with Luria Broth (LB)
plus Kanamycin (100 mg/ml). 10 mL of starter cultures were expanded into 1 L of LB
plus Kanamycin (100 mg/mL) and incubated at 37 oC, 250 µM of IPTG were added to the
culture when log phase was reached and incubated overnight to induce protein expression
at 12 oC. Cultures were then pelleted and resuspended in start buffer (160 mM Imidazole,
4 M Sodium Chloride, 160 mM Sodium Phosphate), a tablet of protease inhibitor (Roche)
was added and the cell suspension was frozen at -20 oC. The cell suspension was thawed
and 10ml of 10x Bugbuster (Novagen), 50 µL of Benzonase Nucleases (Novagen) and 1.7
µL of rLysozyme (Novagen) were added to lyse the cells, the suspension was then gently
tumbled in an orbital shaker for 20 minutes. Lysed cells were pelleted and the supernatant
was filtered through a 0.2 micron filter (Millipore). Supernatants were tumbled with 5 mL
of nickel-NTA resin (Fisher) for 1 hour at 4 oC. The resin was washed then rinsed with
Wash Buffer (50 mM imidazole, 500 mM Sodium Chloride and 160 mM Sodium Phosphate)
and eluted with elution buffer (250 mM Imidazole, 500 mM Sodium Chloride and 20 mM
Sodium Phosphate). Fractions containing the construct of interest were combined and fur-
ther purified by preparative size exclusion chromatography (SEC) on Superdex 75 16/60
(GE Healthcare) at room temperature in PBS or HBS. Fractions containing the protein
of interest were collected, confirmed by SDS page and concentrated by ultrafiltration (Vi-
vaspin, Bioexpress). Protein concentration was determined by measuring UV absorption
signal at 280 nm and calculated from known amino acid composition extinction coefficient.
To facilitate protein quantification in some of the designs was added the GLY-SER-TRP
sequence on the C-terminus.
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5.3.3 Biophysical Characterization
Solution oligomerization state and molecular weight
The monodispersivity and molecular weight were further assess by analytical SEC (Agilent,
1200 series) coupled to an on-line static light scatter (SLS)(miniDAWN TREOS, Wyatt).
The molecular weight determination was performed with the ASTRA software (Wyatt).
Thermal stability
Solution thermostabilities (Tm) were determined by circular dichroism with an Aviv 62A
DS spectrometer. Far-UV wavelength scans (190-260 nm) at concentrations ranging from
20 µM to 90 µM were collected in a 1mm path length cuvette. Temperature-induced protein
denaturation was followed by change in ellipticity at 210 nm.
Nuclear magnetic resonance
One dimensional 1H were recorded at 25 oC on a Bruker DMX 500 MHz spectrometer. The
designed proteins at concentrations ranging from 0.2 to 0.6 mM in Phosphate buffer (pH
7.4).
Surface plasmon resonance
All experiments were carried out on a BIACORE 2000 at 25 oC. Running buffer HBSEP
(0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA and 0.005% (v/v) Surfactant P20)
(GE Healthcare). For analysis designs were immobilized on Research grade CM5 sensor
chip. Designs were immobilized in three flow cells at similar levels (20 to 50 RUs) using
Amine Coupling kit (GE Healthcare) according to the manufacturers manual, the fourth
flow cell was used as reference cell and no design was immobilized. The analyte used was
the Motavizumab Fab, all data were collected using two replicate injections for each concen-
tration. The regeneration was performed with 10 seconds injection of H3PO4 (20x dilution)
from Human Antibody Capture kit. Flow rates during the experiment were maintained
at 50-100 µl/min. Data preparation and analysis were performed using Scrubber software
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(version 2.0, BioLogic Software,Campbell, Australia). For kinetic analysis biosensor data
were globally fit to a mass transport limited simple bimolecular binding model:
A0 represents injected analyte
5.4 Results
5.4.1 Computational Design
The general computational method described is able to generate conformations and se-
quences where a binding or functional site works as a folding nucleus and the remaining
polypeptide chain is folded around to support and stabilize perfectly the precise structure
of the folding nucleus. We supplied an epitope of the RSV virus, a structural motif with
biomedical relevance, to be the folding nucleus, and as template topology a three helix bun-
dle redesigned in a previous work from our laboratory (Correia et al. Structure, Correia
et al. submitted) that has been shown to be a stable protein. The chosen folding nucleus
was crystallized in complex with Motavizumab Fab[140]. When bound to Motavizumab,
the peptide adopts a helical hairpin conformation, which is suitable to become one of the
helical hairpins of the 3-helix bundle. The replaced helical hairpin of the template topology
had 4 residues more in the connecting loop and the RMSD of the backbone of the template
and the folding nucleus was 2.6 A˚.
In the initial folding stage low-resolution models (side chains represented as centroids)
are generated, where the backbone of the folding nucleus is kept rigid and the remain-
ing chain is folded employing C-alpha distance constraints. The side chain conformations
from the residues in the folding nucleus are recovered before the design stage and are held
fixed throughout the procedure maintaining all the atomic detail. The design stage is im-
plemented as an iterative sequence-structure optimization protocol, where three steps of
design[15] and full-atom minimization were performed[111]. The designs were filtered ac-
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cording to Rosetta full atom energy, with the best 50 models by energy were further filtered
according to general structural properties such as: Ramachandran score according the Ra-
machandran backbone dihedral angles distributions[111], counts of polar atoms buried in
the surface of the protein and not involved in hydrogen bonds and packing assessment[112],
all of this scores implemented as Rosetta. Additionally, the designed models were also fil-
tered according a topological criterion selecting for the lowest average bend angle of the 3
helices[149]. The selected models were selected to test the influence of the overall straight-
ness of the designed bundles. The surface positions were designed to be identical to the
surface in the protein used as template topology. Finally, a step of manual design and all-
atom optimization was employed to correct core-packing defects and remove any remaining
polar amino acids from the core. The manual design was employed upon the observation
that designs from the automated stage had alanines overrepresented and valines underrep-
resented, comparing to the template topology.
Given the nature of the iterative-design procedure the designed backbones were highly
intolerable to mutations in the core, consequently in the manual design stage steric clashes
were introduced by the performed mutations and a relax step was necessary to improve the
full-atom energies. The relax step served also as a filtering step to the performed manual
mutations, as a given mutation or set of mutations would only be accepted if the full atom
energy recovered to the initial levels without creating major distortions in the helices local
structure. Computational simulations were performed with a variety of conditions, and as
mentioned, the filtering stage was also employed using different criterion (Table 5.1).
Among the many successes in computational design, several reports have describe the
design of helical bundles but to our knowledge, the strategy of explicitly impose a folding
nucleus in a computational calculation has not yet been explored. To validate the com-
putational approach, eight designs were selected for experimental characterization. The
diversity of the computational designs was observed both in terms of sequence and struc-
ture. Sequence-wise the differences are considerable, with the closest pair of designs differing
by 8 mutations and the most distant pair differing by 42 mutations. The overall core is com-
posed by 45 mutations and the number of mutations relative to the original protein used
as the topological template ranged from 51 to 59 (Table 5.2, Figure 5.5). Structurally the
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Table 5.1: Procedural details of each FFL design. The different parameters used to run the
FFL simulations are summarized as well as the filtering criteria. The manual intervention
stage is also summarized in terms of how many mutations were performed, the initial energy
of the designs and the energy after a full-atom optimization step.
a SD - standard deviation allowed to the constraints derived from target topology
b BS - Binding site design of the positions that are not in direct contact with the antibody
c Filtering criteria based on the helix bend angle as implemented in Helanal[149]
d Rosetta energy after the mutations have been performed and a step of full atom optimization
differences in backbone RMSD of the two most similar models is 0.5 A˚ and the furthest
models are 3.1 A˚ away (Table 5.3). The RMSD differences to the template topology range
from 1.84 to 2.91 A˚. To confirm that the designed sequences indeed show an energetic pref-
erence for the conformation generated we performed a series of structural prediction[111]
simulations where the designed sequences were folded from an extended chain procedure
and no constraints were used. Six out of eight sequences showed a strong preference for
conformations close (∼ 2.5 A˚ away) to the designed conformation (Figure 5.10). In Rosetta
structure prediction simulations some of the sequences also show an energetically favorable
alternative conformation (Figure 5.10).
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Table 5.2: Sequence diversity between designs and template topology. The numbers shown
are the sequence mutations between each construct.
Table 5.3: Structural diversity between designs and template topology. RMSD calculations
are show for the backbone atoms.
5.4.2 Folding and Stability
The designs selected for experimental characterization were generated by different simula-
tions and filtering criteria. The variables were: residues within the binding site that were
allowed to mutate; filtering based on the bend angle of the helical bundle; manual inter-
vention. By having selected designs according different criteria we sought to learn what are
the most robust filtering features and by including a design with no manual intervention we
also wanted to compare a pure computational design with the ones where there was manual
intervention.
From the eight designs experimentally tested, one (FFL 008) was not expressed in E.
coli. The remaining seven were purified by immobilized metal affinity chromatography and
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Figure 5.5: Sequence alignment of the designs and sequence of the protein used as target
topology (T93). Many of the surface residues of the target topology used were imposed in
the designs.
size-exclusion chromatography (SEC). To investigate the multimer solution state the designs
were concentrated up to 0.5 mM and analyzed by analytical SEC on-line with a static light
scatter for molecular weight determination. Only one protein showed multiple molecular
species (FFL 003) (data not shown) while the remaining six designs were monodisperse and
with calculated molecular weights of 14 to 18 kDa, when the expected molecular weight of
the monomeric designed proteins was approximately 15 kDa (Figure 5.6).
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Figure 5.6: Characterization of the oligomeric state of the designs by SEC and SLS. All the
molecules that showed a single monodisperse species had a molecular weight similar to the
expected for a monomeric species, approximately 15 kDa. In green is the UV signal and in
red is shown the light scatter signal.
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Secondary structure content and thermal stability (Tm) of the monodisperse designs
were investigated using CD spectroscopy. The CD spectra of the designs are typical for
alpha-helical proteins showing two minima at 208 and 222 nm. Thermal stabilities ranged
from 48 oC (FFL 002) to higher than 100 oC (FFL 005), the initial scaffold had a Tm of
79 oC. FFL 002 core sequence is a pure Rosetta design with no manual intervention, and
FFL 005 shows a remarkable thermal stability with the wavelength spectra at 25 and 98 oC
being very similar. Notably, FFL 003 and FFL 004 differ by only eight mutations, FFL 003
is not monodisperse and FFL 004 has a thermal stability higher than 85 oC (Figure 5.7 and
Table 5.4).
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Figure 5.7: Secondary structure and thermal stability assessed by CD. On the left panel are
shown wavelength scans, where the designs show typical spectra of all-helical proteins. On
the right panel, thermal denaturation curves are shown and the designs unfold cooperatively
and are reversible. FFL 005 is the exception, a very stable design that did not unfold by
thermal denaturation, as shown by the wavelength scan at 95 oC.
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To further assess the conformational dynamics of the designs proton NMR spectra were
recorded. One-dimensional proton experiments show that the proteins are folded. Further-
more, is possible to observe some spectroscopic signatures of well behaved molecules, such
as, the sharp narrow peaks observed on the amid proton region (9 to 6 ppm) observed for
FFL 001 and well defined signal dispersion on the aliphatic region (1.0 and -1.0 ppm) in
FFL 005. Contrarily, it is also possible to observe that the FFL 007 spectra does not exhibit
any of the ”good” spectroscopic signatures mentioned above[150] (Figure 5.8).
Figure 5.8: 1D 1H-NMR spectroscopy of the FFL designs. In general the designs show good
peak dispersion, signature properly folded molecules.
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5.4.3 Binding to Motavizumab
Ultimately the aim of the computational method developed was to design molecules that
provided the maximal structural support to the folding nucleus, stabilizing the exact con-
formation of the functional site that acted as a folding nucleus. We employed the developed
computational methodology to a broadly neutralizing epitope of RSV that served as folding
nucleus. To assess the validity of the designs we tested the affinities to the motavizumab
using SPR. The designed scaffolds were immobilized on the chip and flowing motavizumab
Fab as the analyte. The six designs showed extremely high affinites to the Fab, ranging
from 795 pM to 29 pM. The tightest binder with the improvement in affinity coming from
a slowest off rate (2.3x10−3s−1 for the highest affinity design 1.196 x 10−4s−1 for the lowest
affinity design)(Figure 5.9 and Table 5.4). The reported affinity for the peptide epitope,
used as a folding nucleus is 230 nM[140], the designs showed a ∼7900 fold improvement. We
speculate that the increase in binding affinity observed on the designed scaffold comes from
exact stabilization of the epitope. Binding of Motavizumab to peptide in solution requires
a significant decrease in entropy of the flexible peptide, which is energetically unfavorable.
Stabilization of the peptide by scaffolding eliminates that entropic barrier. While it is pos-
sible that the increase in affinity is due to additional contacts made by the scaffold outside
the epitope region, the computational modeling suggests that is unlikely. Furthermore, the
affinity of Motavizumab for the F protein of the RSV virus was reported previously as 35
pM, which is similar to several of the designed proteins. We speculate that this affinity is
achieved by accurate mimicry of the binding interaction that occurs with the viral F protein
and the antibody.
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Table 5.4: Thermal stabilities and binding affinities of the FFL designs. Thermal stabilities
were assessed by CD. KDs were determined between motavizumab Fab and the FFL designs.
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Figure 5.9: Binding affinities of the FFL designs to Motavizumab assessed by SPR. The
epitope scaffolds were coupled to the biacore chip and Motavizumab Fab was used as analyte.
The kinetic fits are shown in red.
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5.5 Discussion
The data presented shows that we were able to rationally design new proteins with imposed
functional constraints. Several of the designed proteins, bind with very high affinity, indi-
cating a successful optimization of the functional constraint imposed. Simultaneously, the
designs were highly soluble and thermally stable, showing that the folding free energy was
also efficiently optimized.
The designed molecules are potentially relevant to vaccine research efforts for RSV a
prevalent cause of illness among infants and children. The functional site incorporated is
a well characterized epitope to which multiple neutralizing antibodies bind. The experi-
mental characterization showed that the designed proteins achieved picomolar affinities to
Motavizumab (highest 30 pM; lowest 750 pM). The affinities of the designs are in the same
order of the viral F protein; previous epitope scaffolding effort (Mclellan and Correia in
preparation), based in side-chain grafting (Correia et al., Ofek et al.), was never able to
attain affinities observed in the latest generation. In designed immunogens the affinity for
the antibody to be re-elicited one of the most important features. Remarkably, the designs
showed a high amount of sequence variability for the protein core, in some cases with high
thermal stability.
The methodology described is readily applicable to a myriad of protein design problems,
such as binding site transplantation or enzyme design. For proof of concept, we utilized
a previously observed fold in nature to extract the C-alpha constraints; nevertheless, this
approach can be extended to folds not yet observed in nature. The binding site used was
a contiguous segment but the procedure is also able to deal with discontinuous functional
sites composed by two or more segments, such as catalytic triads. At this point the major
limitation we foresee is the size of the protein to be folded, approximately 150 residues should
be about the upper limit. This limitation is due to computational algorithmic issues related
to the larger space and rugged conformational landscapes available to larger polypeptide
chains.
The design of the FFL proteins is a demonstration that the Rosetta energy function
was able to optimize folding free energy in the presence of functional constraints. Our work
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shows that the field of protein design is maturing at a considerable pace. Here we proposed
a strategy to leverage the accuracy of energy functions together with realistic sampling of
the conformational space to computationally design functional proteins.
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Chapter 6
FINAL DISCUSSION
Throughout my graduate studies the main focus was to develop and apply computational
design methodologies in order to create molecules with biological and therapeutic applica-
tions. In this work I described the concept of designing ”epitope-scaffolds” applied to two
different viruses (HIV and RSV), using both fixed and flexible backbone approaches. Sev-
eral contributions were made for the advance of the fields of computational and immunogen
design:
1. Side chain grafting was used to design a panel of 4E10 epitope-scaffolds;
2. Immunization studies showed that the 4E10 epitope-scaffolds elicited epitope specific
responses;
3. Flexible backbone design methodologies were developed and applied to the removal
of an immunodominant domain;
4. A discontinuous epitope was grafted onto a non-related protein and computational
design was used to leverage in vitro evolution;
5. Development of a novel method with high backbone freedom - Fold From Loops - to
fold and design a protein scaffold around a binding or functional site.
6.1 Design of 4E10 epitope-scaffolds using side chain grafting
As reviewed in the General Introduction, several methods existed to place multiple side
chains in particular geometrical arrangements. Our newly developed side chain grafting
method searches for similar backbones to the epitope of interest, checks structural compat-
ibility of the potential scaffolds with antibody binding and then critical side chains for the
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interaction are grafted. The results obtained show that we were able to transplant con-
tiguous epitopes, achieving exquisite atomic mimicry and improved antibody affinities in
comparison with the epitope peptide. Our rational approach enabled the design of candidate
immunogens with a considerable chance of success.
Side chain grafting was one of the first structure-based strategies employed to trans-
plant linear motifs of broadly neutralizing epitopes from HIV. The epitope-scaffolds repre-
sent advances in the field of immunogen design, where typically many of the candidates for
immunization are the original proteins subunits from pathogens. Often vaccine candidate
molecules are generated in a semi-empirical fashion where structural and biochemical prop-
erties are often compromised. The epitope-scaffolds also surpass the molecular tricks that
evolved on the original proteins from pathogens to escape the immune system. Immuniza-
tion studies were carried with the first generation of side chain grafting epitope-scaffolds.
Sera from immunized rabbits cross-reacted with the 4E10 epitope. Furthermore, experi-
ments using alanine mutants of the 4E10 epitope showed that 4E10-like antibodies were
re-elicited.
Our work is one of the few in the literature reporting elicitation of 4E10-like antibodies,
as this epitope is notoriously poorly immunogenic[57, 65, 66]. The pitfall was the lack of
neutralization capability of the sera elicited by the epitope-scaffolds. The central question
of the project became: if the re-elicited sera specificity matches the 4E10 MAb specificity,
why is it not able to neutralize the virus? Two main future directions are plausible to
improve the lack of neutralization:
a) Importance of the CDRH3 of the 4E10 antibody in virus neutralization. Several
reports had dissected the importance of the CDRH3 for neutralization[61, 62, 63, 64] and
demonstrated that a few mutations on the tip of the CDRH3 (Figure 6.1) reduce the 4E10
neutralization potency without impacting peptide binding. There has been some evidence
that these mutants reduce the interaction of 4E10 antibody with lipid membranes, sug-
gesting that this interaction is important for viral neutralization. The designed epitope-
scaffolds only recreate the 4E10 epitope portion, which seems to be required but insufficient
to achieve neutralization through the 4E10 antibody. A future route is to create epitope-
scaffolds where explicit atomic interactions are required with the CDRH3 of the antibody.
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This extra requirement can be implemented in the matching stage, to search for scaffolds
with pre-existing patches able to interact productively with the 4E10 CDRH3. More ag-
gressive strategies using flexible backbone design approaches to build de novo interaction
patches can also be utilized. In principle, the success of the CDRH3-complementarity de-
signs can be assessed by comparing the affinity of such epitope-scaffolds to wild-type 4E10
versus CDRH3 mutant antibodies; a decrease in affinity to the mutant 4E10 would indicate
that the CDRH3-complementarity designs were successful.
Figure 6.1: 4E10 CDRH3 residues impact virus neutralization. Residues on the tip of the
CDRH3 loop are colored in red and the peptide epitope is colored in yellow.
b) Interaction with the naive germline antibodies. It is hypothesized that to stimulate
potent and specific antibody responses to a particular antigen, one of the key steps is
to interact with naive germline antibodies from the B-cell repertoire. As mentioned, the
epitope-scaffolds were strictly designed to bind to the mature 4E10 antibody; and it was
observed in a recent study that germline predecessors of HIV neutralizing antibodies where
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unable to bind to Env proteins (gp120-gp41) from HIV [151]. Given the ability to trace back
naive antibody germeline sequences[152], we can employ structure-based strategies to model
naive antibodies and design epitope-scaffolds able to bind germline variants. Eventually, this
effort could be extended aiming to engineer scaffolds capable of binding both variants of the
4E10 antibody, becoming an interesting challenge of designing dual-specificity. Nevertheless,
it seems that to accomplish such design the use of in vitro evolution and selection techniques
would be desirable.
Despite the lack of neutralization, the epitope-scaffolds were a test to our knowledge of
vaccine design and which features need to be encoded in efficient immunogens.
6.2 Flexible Backbone design to engineer structure and immunogenic proper-
ties of epitope-scaffolds
At the beginning of my project, few computational designs where backbone flexibility was
employed had been reported, and mainly these designs aimed for structural recapitulation.
Flexible backbone design was employed to remove an extraneous domain of an epitope-
scaffold for 4E10 antibody binding. Beyond the structural objectives, the domain-trimmed
scaffolds aimed to improve immunogenic properties of a 4E10 epitope-scaffold designed
previously using side chain grafting. I devised a protocol that performs backbone sampling
with pre-defined secondary structure, which was combined with RosettaDesign and finalized
with a filtering stage to select designs with native-like features. The flexible backbone
procedure yielded several designs that were soluble and with improved thermal stability
relative to the parent molecule. One of the designs was crystallized and showed close
agreement with the computational model. During the maturation of our method two other
articles reported the use of flexible backbone design[48, 49]. Nevertheless, our strategy still
remains general and adequate to several applications that might not be straightforward with
the other reported approaches:
a) Hu et al.[48] reported the design of a new loop conformation. The starting backbones
that were designed designed were selected from a structural database of loops with length
12. In our flexible backbone protocol, backbones were generated by fragment assembly
conferring an extra layer of conformational sampling. Possibly, future design problems might
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require the creation of backbone conformations not yet observed in the structural space
available, hence assembling fragments to create structural diversity might be necessary.
b) Murphy and coworkers [49] also designed backbones generated from fragment assem-
bly. But they used a pre-placed side chain central to the catalytic activity, constraining the
loop conformations sampled. The loop built was 5 residues long, while in our case helix-loop
segments with 16 and 17 residues were built, and 24 residues were designed in a protein
with 120 residues.
Sera from immunizations with the parent scaffold cross-reacted strongly with the scaf-
fold itself. Further analysis of the parent scaffold’s sera showed weak cross-reactivity with a
trimmed epitope-scaffold. This result confirmed that the majority of the antibodies in the
sera were directed to the removed domain. The domain-trimmed scaffold lacks an immun-
odominant domain that might hinder epitope specific responses. Domain trimming and
resurfacing (also described in Chapter 3) are valid structure-based strategies to generate
panels of epitope-scaffolds that can be used for multiple applications. Frequently in im-
munization experiments, multiple antigens are used sequentially or combined to stimulate
specific antibody responses, therefore variants of the epitope-scaffolds might be appropriate
to be used in such immunization schemes. Additionally, these panels of optimized epitope-
scaffolds are valuable reagents to dissect epitope specificities of polyclonal sera.
Methodologically, it would be important to test the protocol on the design of other sec-
ondary structure motifs, to further evaluate how general it can be. The principles developed
in this domain trim problem served as a proxy to deal with more complex design problems.
6.3 Grafting of a complex epitope using computationally inspired directed li-
braries
Many of the epitopes and protein binding sites are not contiguous in sequence, but are
comprised within multiple discontinuous segments of the protein, coming together in the
tridimensional structure to form the interaction site. Given the necessity of scaffolding
complex epitopes the Multigraft protocol was developed. Multigraft was applied to the b12
epitope from gp120, and we sought to transplant a ”minimimal” b12 epitope were only the
2 core loops responsible by most of the contacts were considered. The structural complexity
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of this design and the lack of success of the computational approach, suggested the need for
high-throughput screening and selection of designs with affinity for the b12 antibody.
A yeast display platform was used to screen directed libraries that were assembled ac-
cording to sequence profiles generated by computational design calculations. Here, I devised
an iterative flexible backbone design protocol where individual segments of the scaffold were
optimized and then recombined. The rational was to first stabilize the local conformation
of each loop and after the recombination step, optimize the correct spatial orientation be-
tween them. A naive library allowing the 20 amino acids in all the positions hypothesized
to be relevant for the stabilization of the 2 loops would span a sequence space of size ap-
proximately 1021; a Rosetta library including all the amino acids observed in computational
designs would have the size of 1017; finally, after a strict filtering based on structural fea-
tures of the computational models the library size was reduced to 1012. In order to enable
the screening using yeast display, the library was split in two, each targeting one of the
loops of the epitope. We achieved an improvement of 30,000 fold over the initial compu-
tational design. The best clones selected bound in the same affinity range of the original
gp120-b12 interaction. To our knowledge, this was the first successful transplantation of a
complex binding site onto a non-related protein. The results suggest that computational
sequence-structure ensembles may carry useful information to guide the construction of
directed libraries, particularly useful if aggressive structural intervention is required.
Some groups started to explore the strategy of designing computationally inspired li-
braries [123, 124], but in some of these reports the aim is to recapitulate in silico results of
selection experiments[153]. In our case the challenge was more demanding, since the starting
library was designed from computational calculations. Utilizing high-throughput selection
techniques has many advantages over the typical expression-purification-characterization of
tens to hundreds of different constructs. It is possible to screen many more sequences in a
combinatorial fashion increasing the chances of success, therefore providing valuable input
to benchmark and improve the design methodologies. Another advantage of using computa-
tional guided libraries is that, in principle the chances of evolving clones with binding sites
that were not pre-determined is greatly reduced, often unexpected results occur in random
evolution experiments.
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Structural characterization of successful constructs is still in progress and it will be
essential to evaluate and improve the current computational protocol. In future implemen-
tations, we aim to make the protocol fully automated. It would be particularly interesting
to implement an automated recombination step, where multiple Rosetta trajectories run-
ning independently in different nodes of a computational cluster could communicate and
recombine their best solutions to further diversify the search space.
6.4 Transplantation and stabilization of functional sites by folding and design
a protein around structural motifs
One of the major limitations of the scaffolding methods described above (Side chain grafting
and Multigraft) is that both are critically dependent on a matching stage to find compati-
ble scaffolds with the structural motif to be transplanted. During my PhD project I imple-
mented and developed a computational method named Fold From Loops (FFL). Essentially,
the procedure takes a structural motif and a protein topology, and by extracting distance
constraints from the topology is able to fold a similar structure around the motif of interest.
Two main fundamental differences between FFL and the methods previously describe:
a) FFL only requires a topological description of the protein to be folded disregarding
atomic level details that both side chain and backbone grafting matching consider;
b) in FFL side chains or backbones are not being imposed to pre-existing protein struc-
tures, but instead most of the protein is flexible allowing proper accommodation and struc-
tural stabilization of the fixed functional site.
FFL was tested on a broadly neutralizing epitope from RSV which is structurally defined
as a helical hairpin. A three-helix bundle was used as template for the topology to be folded.
The best designs showed low pM affinities towards the cognate antibody (Motavizumab).
In contrast to the nM afinities of previous scaffolds designed with an extension of the side
chain grafting method (Mclellan and Correia, in preparation). So far, the results suggest
that the FFL method is promising for the transplant of structural motifs.
The FFL protocol represents an advance in protein design algorithms, where functional
and structural constraints are incorporated in the computational simulation. These con-
straints bias the overall structure to provide support to the functional site. It is also a long
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waited development to the design exclusively for structural purposes, such as the design of
the right handed coiled coil[19] and the new globular topology (Top7)[21]. For further devel-
opment and validation of the FFL computational methodology, structural characterization
is essential and is work in progress. For future applications, an appealing and important
challenge is to fold proteins around two or three discontinuous protein segments, allowing
the design of more diverse protein functions. The FFL algorithm could be a valid alterna-
tive to current enzyme design algorithms that place catalytic side chains onto pre-existing
backbones without allowing any flexibility[30, 31, 32].
Overall in this thesis several advances are described, both in terms of immunogen design
and methodological developments of general protein design. It is advantageous to have
multiple computational design strategies available, providing appropriate alternatives to
approach distinct design problems. In immunogen design, there is a broad future perspective
for the developed methods, given that the active discovery of new broadly neutralizing
antibodies provides novel templates for structure-based approaches. The methods described
here will certainly benefit from parallel efforts of the scientific community, in particular on
the development of more accurate energy functions and more realistic sampling methods.
These improvements will contribute to the design of proteins with greater confidence, better
success rates and the engineering of the most useful and creative protein functions.
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